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PREFACE 
This report covers the activities of the Research Triangle Institute's Biomedical Applications Team pro-
gram for the period 1 January 1981 through 31 December 1981. The work was performed in the Research 
Triangle I nstitute's Center for Technology Applications under the direction of Dr. D. J. Rouse. Dr. J. N. 
Brown, Jr., Director of the Center, participated in the methodology development and management of the 
team. Assistance in the development of marketing. strategy was provided by Dr. W. H. Clingman of 
William H. Clingman and Company, Inc., a marketing and management consulting firm. Other participants 
in the program were Dr. H. C. Beall, Mr. R. E. Eakes, Mr. P. N. Kizakevich, Dr. M. McCartney, and 
Ms. B. Bass . 
. The work reported herein was supported by the National Aeronautics and Space Administration--
Contract No. NAS1-16177. Mr. John Samos, Head, Technology Utilization and Applications Programs Office, 
Langley Research Center, was the technical monitor. 
The authors gratefully acknowledge the contributions of many individuals to the success of the RTI 
Biomedical Applications Team program. The time and effort contributed by managers, engineers, and 
scientists throughout the National Aeronautics and Space Administration, and that of medical researchers 
and clinieians, were absolutely essential to program success. Industry managers and technical staff have 
always been cooperative and open in their participation. Continuing discussions with these industry repre- . 
sentatives have enhanced the team1s understanding of medical device manufacturing and marketing practices 
and constraints. The continued contribution to the team1s efforts by Dr. F. Thomas Wooten, an RTI Vice 
President, is appreciated. Finally, Mr. John Samos has contributed significantly to the success of the 
program, and, as a technical monitor, he has always been supportive. 
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ABSTRACT 
The objective of the Research Triangle Institute CRTI) Biomedical Applications Team is to achieve wide-
spread utilization of National Aeronautks and Space Administration (NASA) technology in medicine. This 
objective is best obtained by stimulating the introduction of new or improved commercially available medical 
products incorporating aerospace technology. 
A bipolar donor-recipient model of medical technology transfer is presented to provide a basis for the 
team1s methodology. That methodology is designed to: (1) identify medical problems and NASA technology 
that, in combination, constitute opportunities for successful medical products, (2) obtain the early partic-
ipation of industry in the transfer process, and (3) obtain acceptance by the medical community of new 
medical products based on NASA technology. 
During the reporting period, the team completed two commercial transfers: the Stowaway, a light-
weight wheel~air that provides mobility for the disabled and elderly in the cabin of commercial aircraft, 
and. Micromed , a portable medication infusion pump for the reliable, continuous infusion of medications such 
as heparin or insulin. The team also completed a study of the marketing and manufacturing factors critical 
to the commercialization of the lightweight walker incorporating composite materials. 
The team identified five new· projects. Eleven projects were inactivated as a result of completed trans-
fers or inadequate commercial potential to justify continued· development. During the reporting period, 
progress was made in the development and commercialization of each of the 18 currently active projects. 
For the convenience of the reader, the names and addresses of the sources of certain commercial 
products are included in this report. This listing does not constitute an endorsement by either the National 
Aeronautics and Space Administration or the Research Triangle Institute. 
iii 
TABLE OF CONTENTS 
PREFACE 
ABSTRACT .. 
1.0 INTRODUCTION. 
1.1 Biomedical Applications Team Objectives 
1.2 Biomedical Applications Team Staffing . 
1.3 Participating Institutions ..... . 
1.4 Publications, Presentations, and Conference Attendance 
1.5 Report Summary. . 
1.6 Definition of Terms 
1 .7 References.... 
2.0 TECHNICAL APPROACH. 
2.1 Conceptual Framework for Medical Technology Transfer. 
2.2 Biomedical Applications Team Methodology 
2.2.1 Identification of Opportunities 
2.2.2 Screening .......... . 
2.2 :3.Commercialization Strategies 
2.2.4 ·Implementation and Monitoring. 
2.3 References ........... . 
3.0 COMMERCIALIZATION ACTIVITIES: 
3.1 Aircraft Wheelchair: The Stowaway 
3.1.1 Background.......; 
3.1.2 Development and Commercialization of the Stowaway .. 
3. 1.3 Description of the Stowaway. . . . . . 
3.1.4 Aircraft Wheelchair Summary ..... ~ 
3.2 Parker Hannifin: Biomedical Products Division 
3.2.1 Prostheti® Urinary Sphincter .... . 
3.3.2 Micromed .............. . 
3.2.3 Programmable Implantable Medication System 
3.2.4 Parker Hannifin Biomedical Products Division 
iv 
,. 
iii 
1 
1 
2 
3 
4 
10 
10 
12 
13 
13 
15 
17 
18 
19 
22 
22 
24 
24 
24 
24 
25 
27 
28 
28 
29 
29 
30 
TABLE OF CONTENTS (continued) 
4.0 SPECIAL PROJECTS. . ................. . 
4.1 Cerebrospinal Fluid Control System: Phase 0 Study. 
4.1.1 Literature Review ........... . 
4.1.2 Interviews . . . . . . . . . . . . . . . 
4.1.3 Action ................ . 
4.2 AAMI Standards Development for Medical Devices. 
4.2.1 Standards Development Process.. . . . . 
4.2.2 RTI Biomedical Applications Team Activity. 
4.2.3 Transfer Opportunities . . . . . . . 
4.2.4 Conclusions .............. . 
4.3 Composite Materials Walker: Market Study. . .. 
4.3.1 Description of Graphite/Epoxy Walker .. 
4.3.2 Patient Population for Lightweight Walker 
4.3.3 ManufacturJog- and Marketing Considerations . 
4.3.4 Status and Action ...... . 
4.4 References ......... · .... . 
5.0 STATUS OF ACTIVE TRANSFER PROJECTS. 
Composite Material Applications . . . . . . 
Detection of a Dislodged Temperature Probe 
Fiber Optics System for Knee Surgery. 
Flow Sensor for an Infusion Pump. 
Hydrocephalus Shunt--Ventilation 
Implant Materials Testing . . . 
Low-Cost UV Optical Dosimeter. 
Microwave Thermography. . . . 
Noninvasive Lung Diagnosis. . 
Ophthalmic Screening Device .. 
Portable Cooling System for Quadriplegics 
Programmable Implantable Medication System 
Prosthetic Urinary Sphincter . . . . . . . 
Texturing for Percutaneous Connectors.. . 
Texturing Surfaces for Cardiovascular Prostheses 
v 
Page 
34 
34 
35 
40 
44 
45 
45 
46 
46 
47 
49 
49 
49 
50 
51 
51 
53 
53 
56 
60 
63 
65 
67 
69 
72 
74 
77 
79 
82 
87 
91 
93 
TABLE OF CONTENTS (continued) 
6.0 INACTIVATED PROJECTS. 
Analysis of the Retinal Reflex 
Analyzer of Tissue Viability 
Biological Tissue Freezing System 
Esophageal Pressure Transducer. 
Hearing Aid Intelligibility 
Neuromuscular Diagnostic Unit. . 
Pressure Transducer Calibrator . 
Retractor Tool for Brain Surgery 
Selective Call Telemetry 
Texturing Dental Implants. 
Weight Alleviation Device 
7.0 CONCLUSIONS .. ; .. 
APPENDIXES 
A. Publications and Presentations 
B. Travel ........ . 
C. Project Activity Summary 
D. Problem Statements . . . 
vi 
Page 
96 
96 
96 
96 
97 
97 
97 
98 
98 
98 
98 
99 
100 
A-1 
B-1 
C-1 
D-1 
1.0 INTRODUCTION 
The preamble to the Space Act of 1958, which created the National Aeronautics and Space Administration, 
states: lilt is the policy of the United States that activities in space should be devoted to peaceful pur-
poses for the benefit of all mankind ."1 This Act of Congress further charges NASA with providing "for 
the widest practical and appropriate dissemination of information concerning its activity and the results 
thereof. II The NASA Technology Utilization Program was initiated in 1962 to assist in satisfying this Con-
gressional obi igation. 
Since 1962, NASA has been a 
technology tranfer programs. 
I ndustrial Applications Center 
search to the non-space-related 
leader and an innovator in the establishment, operation, and evaluation of 
Through its Tech Briefs, special publications, technology surveys, and· 
programs, NASA has successfully transferred the results of a~rospace re-
sector~ of society. 2 
In 1966, NASA introduced a new approach to technology transfer that involved the activities of multidisci-
plinary "applications teams. II The objective of these applications teams--called Biomedical Applications Teams 
(BATeams)--was to effect the transfer of NASA technology to applications in medical research and clinical 
medicine. The general approach of the Biomedical Applications Teams was: (1) to identify problems 
through direct interactions with clinicians and medical researchers, (2) to identify potentially applicable 
NASA technology by a variety of mechanisms, and (3) to take necessary and appropriate action to effect 
actual utilization of NASA technology in solving technology-related medical problems. 
The Research Triangle Institute has participated in this program since 1966, when it established one of the 
first three NASA Biomedical Applications Teams. Since then, the Institute has made a major commitment to 
the successful transfer of aerospace technology to applications in medicine and to a better understanding 
and advancement of the technology transfer process. 
1.1 Biomedical Applications Team Objectives 
The primary objective of the Biomedical Applications Team program is to assist NASA in achieving wide-
spread utilization of aerospace technology in the medical field. Widespread utilization implies that, by 
applying NASA technology to medicine, a significant sector of the medical field and of those seeking 
medical services realize some benefit. Implicit in this program objective is that widespread utilization 
be realized in a relatively rapid manner. . 
The successful transfer of NASA technology to applications in the medical field via the Biomedical Ap-
plications Team program has been demonstrated, 2 3 both in clinical medicine and in medical research. 
These applications have resulted in advances in medical research, improved clinical diagnoses and 
treatments, and the introduction of new or improved medical products. 
While advances in medical research ultimately have widespread positive impact on the delivery of 
health care in the United States, medical research is a slow, complex, and expensive process. On 
the other hand, much can be accomplished in a relatively short time by solving technology-related 
problems in clinical medicine. Applications of technology in clinical medicine usually involve the intro-
duction of a new or improved commercially available medical product. Thus, the approach of the NASA 
Biomedical Applications Teams in obtaining widespread utilization of NASA technology is to direct their 
efforts primarily to solving problems that involve the introduction of a new or improved medical prod,.. 
uct. 
This emphasis on achieving widespread utilization by commercializing NASA technology is reflected in 
the activities and methodology of the Biomedical Applications Team program. The team methodology 
has been built around the following four activities: (1) identifying medical problems and needs and 
potentially applicable NASA technologies that together constitute a new or improved medical product, 
(2) screening opportunities to find those that represent potentially successful commercial products, 
(3) developing commercialization strategies that take into account any necessary adaptation of NASA 
technology, evaluations and clinical trials, FDA regulations, manufacturer's marketing systems, and 
required funding, and (4) implementing and monitoring commercialization strategies. These tasks are 
discussed in more detail in Section 2.0, Technical Approach. 
1.2 Biomedical Applications Team Staffing 
The· RTI Biomedical Applications Team is a multidisciplinary team of engineers and scientists, whose 
educational backgrounds include physiology,. biophysics, engineering, biochemistry, and biomedical 
engineering, and whose experience includes basic and applied research, product development, and 
marketing. The team is necessarily multidisciplinary in nature because the transfer of technology to 
the medical field is an interdisciplinary process. That is, team members must communicate precisely 
and effectively with physicians, NASA scientists and engineers, industry representatives, and repre-
sentatives of a variety of government agencies. Furthermore, the team must be able to deal with and 
contribute to the technical, clinical, financial, legal, marketing, and regulatory aspects of introducing 
new medical products. The individuals who participated in the RT I Biomedical Applications Team pro-
gram during the reporting .period are: 
Name Professional Background 
Dr. J. N. Brown, Jr. Electrical Engineer 
2 
Responsibility 
Director, Center 
for Technology 
Applications 
Name Professional Background Reseonsibilit~ 
Dr. D. J. Rouse Biochemist, Physiologist Director, RTI BATeam 
Dr. H. c. Beall Biophysicist, Physiologist Solution Specialist 
Dr. w. H. Clingman Chemical Engineer Marketing Consultant 
Mr. R. E. Eakes Biomedical Engineer Solution Specialist 
Mr. P. N. Kizakevich Biomedical Engineer Internal Technical 
Consultant 
Dr. M. McCartney Biomedical Engineer Internal Technical 
Consultant 
Ms. B. Bass Resource Specialist Solution Assistant 
1.3 Particieating Institutions 
Biomedical Applications Teams may be viewed as one component in a technology transfer network that 
involves individuals at NASA Headquarters, NASA field centers, medical institutions, manufacturing 
and marketing firms, the National Institutes of Health (NIH), the Food and Drug Administration (FDA), 
and other government agencies. Organizations and their roles in the technical process are listed 
below. 
Organization 
National I nstitutes of Health 
National Aeronautics and Space 
Administration 
Medical institutions 
3 
Role 
Establishment of medical objectives and 
priorities and evaluation of devices 
Development of advanced technology and 
innovations 
Specification of needs and use of medical 
innovations 
Organization 
Industry 
Biomedical Applications Teams 
Food and Drug Administration 
Role 
Manufacture and distribution of products 
Coordination, planning, and reporting 
Approval of products and establishment of 
medical objectives and priorities 
At present, medical researchers and clinicians from 28 medical institutions participate in the RTI Bio-
medical Applications Team program. Medical researchers and clinicians participate in the program by: 
(1) identifying medical problems and needs appropriate for investigation by the Biomedical Applications 
Team, (2) serving as a knowledge base on medical problems and needs, markets, and potential appli-
cations of NASA technology, and (3) receiving NASA technology to be applied in their medical research 
programs or to be evaluated within their clinical practices. Figure 1 presents the geographical loca-
tions of participating medical institutions and NASA field centers. Table 1 lists these medical institu-
tions, and Table 2 lists the RTI Biomedical Applications Team active projects at the NASA field centers 
for the past year. 
The active participation of medical device manufacturers is essential to the widespread utilization of 
NASA technology because they incorporate that technology into commercial medical products. Manu-
facturers who have participated in the RTI Biomedical Applications Team program during this reporting 
period are listed in Table 3. 
Government agencies involved in health care research, regulation, and delivery work with the RT I team 
to identify significant projects and to facilitate their successful completion. Agencies participatin~ in 
RTI's team projects during this reporting period are listed in Table 4. 
1.4 Publications, Presentations, and Conference Attendance 
To inform the medical community of NASA's technology transfer program in medicine, RTI team mem-
bers publish journal articles and partiCipate in biomedical conferences. These activities stimulate 
the discussion of technical needs. in medicine with clinicians and new product opportunities with med-
ical device manufacturers. A recent article published in Medical I nstrumentation by D. J. Rouse, 
J. N. Brown, Jr., and R. P. Whitten entitled "Methodology for NASA Technology Transfer in Med-
icine" described the biomedical technology transfer program. Publications and conference presentations 
for the reporting period are presented in Appendix A. Other significant travel is described in 
Appendix B. 
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Figure 1. Biomedical Technology Transfer Network. 
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TABLE 1. PARTICIPATING MEDICAL INSTITUTIONS 
Alabama School for the Deaf 
Albert Einstein College of Medicine 
Baylor College of Medicine 
Ben Taub Hospital 
Case Western Reserve University 
Cornell Medical Center 
Duke University Medical Center (including VA Hospital) 
Eastern Virginia Medical School 
Johns Hopkins University Medical School 
Johnston R. Bowman Health Center 
M. D. Anderson Hospital 
Maryland I nstitute Emergency Medical Services 
Medical College of Virginia 
Montefiore Hospital 
Red Cross Blood Research Laboratory 
Rochester General Hospital 
Rush-Presbyterian Medical Center 
St. Mary's Hospital 
Texas Institute for Rehabilitation and Research 
University of Alabama Department of Rehabilitation 
University of California-I rvine 
University of Mississippi Medical Center 
University of North Carolina School of Medicine 
University of Virginia Rehabilitation Engineering Center 
University of Virginia School of Medicine 
Veterans Administration Hospital 
Veterans Administration Hospital 
Wadley Institute 
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Talladega, AL 
Bronx, NY 
Houston, TX 
Houston, TX 
Cleveland, OH 
New York, NY 
Durham, NC 
Hampton, VA 
Baltimore, MD 
Chicago, IL 
Houston, TX 
Baltimore, MD 
Richmond, VA 
New York, NY 
Bethesda, MD 
Rochester, NY 
Chicago, IL 
Richmond, VA 
Houston, TX 
Birmingham, AL 
Irvine, CA 
Jackson, MS 
Chapel Hill, NC 
Charlottesville, VA 
Charlottesville, VA 
Norfolk, VA 
Houston, TX 
Dallas, TX 
TABLE 2. PROJECTS WITH NASA FIELD CENTERS DURING REPORTING YEAR 
AMES RESEARCH CENTER 
Digital Data Recorder for Physiological Monitoring 
Liquid-Cooled Garment Projects 
Cooling Vests for Quadriplegics 
Cooling for Multiple Sclerosis Therapy 
GODDARD SPACE FLIGHT CENTER 
Analyzer of Tissue Viability 
Biological Tissue Freezing System 
Programmable Implantable Medication System 
JET PROPULSION LABORATORY 
Hydrocephalus Shunt--Ventilation 
JOHNSON SPACE CENTER 
Female I ncontinence Device 
Flow Sensor for an I nfusion Pump 
Physician's Black Bag 
Pressure Transducer Calibrator 
KENNEDY SPACE CENTER 
High Performance Wheelchair 
LANGLEY RESEARCH CENTER 
Aircraft Wheelchair 
Analyzer of Tissue Viability 
Composite Material Applications 
Fiber Optics for Knee Surgery 
High Performance Wheelchair 
Implant Materials Testing 
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LANGLEY RESEARCH CENTER (continued) 
Low-Cost UV Optical Dosimeter 
Microwave Thermography 
Neuromuscular Diagnostic Unit 
Noninvasive Lung Diagnosis 
Weight Alleviation Device 
LEWIS RESEARCH CENTER 
Detection of a Dislodged Temperature Probe 
Hydrocephalus Shunt--Ventilation 
Texturing for Percutaneous Connectors 
Texturing Surfaces for Cardiovascular 
Prostheses 
MARSHALL SPACE FLIGHT CENTER 
Analysis of the Retinal Reflex 
Detection of a Dislodged Tempera-
ture Probe 
Ophthalmic Screening Device 
Prosthetic Urinary Sphincter 
Retractor Tool for Brain Surgery 
TABLE 3. MANUFACTURERS PARTICIPATING IN BATEAM PROJECTS 
Abbott Laboratories 
Advex Corporation 
Air Transport Association 
American Hospital Supply 
American Polarizers, Inc. 
Applied Medical Technology, Inc. 
B&K Instruments 
Bardon Enterprises, Inc. 
Bell & Howell 
CAMI Health Care, Inc. 
Chesebrough-Ponds, Inc. 
Cryomed 
Eagle Engineering Corporation 
Electro-Optics Consu Itants, Inc. 
Everest & Jennings 
Hercules, Inc. 
I nvacare Corporation 
Inductron 
JWM Company 
Lumex Corporation 
Major Laboratory 
Medic 
Medical Engineering Corporation 
Melton Company 
Microwave Associates, Inc. 
Miller Medical Electronics 
NARCO 
Pacesetter Systems, Inc. 
Palm Beach Medical Corporation 
Parker Hannifin Corporation 
Patscenter International, Inc. 
Preston Company 
Pudenz~Schulte Medical Research Corporation 
Scientific Industries 
Thermo Electron Corporation 
Union Carbide 
United Airlines 
United States Manufacturing Company 
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Houston, TX 
Hampton, VA 
Washington, DC 
Glendale, CA 
Philadelphia, PA 
Lakewood, OH 
Cleveland, OH 
Hampton, VA 
Pasadena, CA 
League City, TX 
Trumbull, CT 
Mt. Clemmons, MI, 
Houston, TX 
Huntsville, AL 
Los Angeles, CA 
Washington, DC 
Elyria, OH 
Grafton, VA 
Philadelphia, PA 
Bay Shore, NY 
Oklahoma City, OK 
Sun Valley, CA 
Racine, WI 
Oklahoma City, OK 
Burlington, MA 
San Diego, CA 
Houston, TX 
Sylmar, CA 
E. Long Meadow, MA 
Irvine, CA 
Princeton, NJ 
New York, NY 
Irvine, CA 
Bohemia, NY 
Waltham, MA 
Tunedo, NY 
San Francisco, CA 
Pasadena, CA 
TABLE 4. AGENCIES PARTICIPATING IN BATEAM PROJECTS 
Administration on Aging 
Agency for I nternational Development 
American Foundation for the Blind 
American Red Cross 
Department of Transportation 
Environmental Protection Agency 
Food and Drug Administration 
Gerontological Society of America 
National Bureau of Standards 
National Cancer Institute 
National Heart, Lung, and Blood Institute 
National Institute on Aging 
National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases 
National Institute of Child Health and Human Development 
National Institute of Handicapped Research 
National I nstitute for Occupational Safety and Health 
National Institute for Dental Research 
National Institute of Neurological and Communicative Disorders and Stroke 
Paralyzed Veterans of America 
Rehabi litation International-USA 
Texas Rehabilitation Commission 
U. S. Coast Guard 
Veterans Administration 
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1.5 Report Summary 
The Biomedical Applications Team's technical approach to technology transfer in medicine is described 
in Section 2.0. Emphasis on the commercialization of NASA technology is evident throughout the team's 
methodology; that is, the team's activities are divided into four major phases leading logically from 
the identification of opportunities for commercialization to the implementation and monitoring of com-
mercialization strategy. Within each of these four phases, program flexibility allows for technology 
transfer activities related to medical research and institutional technology transfer. 
The commercialization activities presented in Section 3 summarize the two commercial transfers com-
pleted by the RT I team during the reporting period: the Stowaway, a lightweight w~eeJchair that 
provides mobility for the disabled in the cabin of commerCial aircraft, and Micromed , a portable 
medical infusion pump for the reliable, continuous infusion of medication such as heparin or insulin. 
A report on the cerebrospinal fluid control system Phase 0 study is presented in Section 4.1. The 
team's research on standards development committees as resources for the identification of technical 
needs in medicine is presented in 4.2. Section 4.3 summarizes an RTI team study on the manufactur-
ing and marketing factors critical to the commercialization of a lightweight walker made of composite 
materials. 
The team's problem solving and transfer activities in active transfer projects are summarized in Sec-
tion 5.0. Projects inactivated during the reporting period are discussed in Section 6.0. 
Section 7.0 is a statement of conclusions and recommendations. This section emphasizes what has been 
learned concerning medical technology transfer and how these lessons may be applied to increase the 
effectiveness of the NASA Biomedical Applications Team program. 
Publications and presentations by the team· are presented in Appendix A. Significant travel is sum-
marized in Appendix B. A summary of the. team's project activities for the reporting period is pre-
sented in Appendix C. Problem statements describing medical requirements for improved technology, 
as identified by the team during the reporting period, are presented in Appendix D. 
1.6 Definition of Terms 
Biomedical Applications Team--A multidisciplinary group of engineers and scientists engaged in assist-
ing NASA in achieving widespread utilization of aerospace technology in the medical field. 
Commercial opportunityuThe combination of a significant medical need or problem and appropriate, 
relevant NASA technology that constitutes the basis for a potentially successful new or improved com-
mercial medical product. 
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Commercial technology transfer--The successful development and marketing of a new or improved med-
ical product that incorporates NASA technology. 
Computer information search--A computerized search of NASA's aerospace information bank at one of 
six Industrial Applications Centers (lACs). This information bank consists of more than 1 million 
documents that have been indexed and abstracted in the Scientific and Technical Aerospace Reports 
(STAR) and the I nternational Aerospace Abstracts (IAA). 
Donor--Organization or individual who originally developed technology that is transferred. Within the 
context of the Biomedical Applications Team, NASA is the donor. 
Institutional technology transfer--The application of NASA technology to solve a significant medical 
problem that does not result in a new or improved medical product. 
Medical problem (or need)--A specific and definable technology-related medical problem or need that 
cannot be satisfied by commercially available equipment or by the information available to the problem 
originator through routine information channels. 
Participating institution--A medically oriented educational institution, hospital, medical center, or' 
government agency that works with the Biomedical Applications Team in identifying medical problems 
and needs and in evaluating NASA technology that represents solutions to those problems and needs. 
Problem originator--A clinician or medical researcher actively involved in reaching a specific medical 
objective and faced with a specific technology-related problem or need. 
Problem statement--A concise, written description of a medical problem or need that contains sufficient 
details to allow a computer search to be performed and that contains sufficient information to enable 
NASA engineers and scientists ~o consider possible solutions. 
Recipients--The clinical medical sector or medical researcher who uses or applies the technology trans-
ferred. 
RTOP (Research and Technology Objectives and Plans)--A proposal submitted by a NASA field center 
to NASA Headquarters for funding of research and development projects. 
Technology--AII of the skills, techniques, and understanding that constitute a specific technology. 
Technology includes, but is not limited to, hardware. 
11 
Technology transfer--I nstances in which a specific technology moves from one .situational context--the 
one for which it was developed--to another. As a result, changes are seen in either the technology 
or the situation to which it is moved or both. 
Transfer agent (or linker)--The individual or organization that plans, stimulates, and facilitates tech-
nology. Within this context, the transfer agent or linker is the Biomedical Applications Team. 
1 .7 References 
1. Public Law No. 85-568, National Aeronautics and Space Act of 1958. 
2. Haggerty, J. J. Spinoff 1981--An Annual Report. National Aeronautics and Space Administra-
tion, April 1981. 
3. Rouse, D. J. Applications of Aerospace Technology in Biology and Medicine. Research Triangle 
Institute, Research Triangle Park, North Carolina, December 1980. 
4. Rouse, D. J., J. N. Brown, Jr., and R. D. Whitten. Methodology for NASA Technology Trans-
fer in Medicine. Medical Instrumentation, Vol. 15, No.4, pp. 234-236, July-August 1981. 
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2.0 TECHNICAL APPROACH 
The objectives, operations, and methodology of the RTI Biomedical Applications Team are presented in this 
section. The conceptual framework for medical technology transfer described in Section 2.1 provides the 
background and rationale for the Biomedical Applications Team methodology as developed by the Research 
Triangle I nstitute and presented in Section 2.2. 
2.1 Conceptual Framework for Medical Technology Transfer 
A conceptual framework for medical technology transfer is diagrammed in Figure 2.1 The framework 
is basically a bipolar donor- recipient model. The role of the donor, in thfs case NASA, is to reveal, 
disseminate, and promote technology. The role of the recipient, the medical community, is to seek 
out, evaluate, and utilize technology. 
As explained in the introduction, the primary thrust of the Biomedical Applications Team program is 
to transfer technology by the introduction of new and improved medical products. Thus, a manufac-
turer of those products is included in Figure 2. Medical technology transfer normally involves the 
identification of a medical problem or need within the medical community. In response, the National 
Aeronautics and Space Administration recognizes the relevance of specific aerospace technology and 
makes that technology available. The manufacturer designs, develops, evaluates, and markets a new 
or improved medical product that incorporates aerospace technology and represents a solution to the 
medical problem or need. 
The purpose of the transfer agent* in this framework is to plan, stimulate, and facilitate such tech-
nology transfer. This is the role of the Biomedical Applications Team. 
Research into the process of medical technology transfer at the Syracuse University Research Center 
has concluded that the donor, recipient, and manufacturer are frequently at cross purposes. 2 The 
recipient is primarily concerned with solving a problem. The manufacturer, by necessity, is con-
cerned with introducing a commercially successful product. The donor obtains satisfaction as reward 
for involvement in the transfer process. I t is the task of the transfer agent to bring the donor, 
recipient, and manufacturer· together in such a way that each views successful technology transfer as 
the primary objective. A technology transfer methodology based upon an active transfer agent serving 
as a personal interface has evolved from the realization that the passive disse'1lination of information 
on technology in itself seldom results in effective technology transfer. This point is illustrated by a 
*The term IIlinker li is frequently used in this context. 
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Figure 2. Conceptual Framework for Medical Technology Transfer. 
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quote from a Congressional Review of Intergovernmental Dissemination of Federal Research and Develop-
ment Results. 3 
The mere availability of information does not cause its transfer or use. Printed 
materials alone, even expertly prepared, cannot stimulate interpersonal relations, define 
a problem, answer related questions, involve consulting authorities, provide follow 
through on problems or relate to other agencies. 
The specific role of the Biomedical Applications Team depends upon the motivation, competence, and 
organization of the donor, recipient, and manufacturer. NASA is highly motivated to transfer aero-
space technology to applications in non-space-related fields. Further, its organization is structured 
to facilitate the development of sophisticated and advanced technology. NASAls understanding of the 
medical industry and clinical medicine, on the other hand, is limited. The technological competence of 
the recipient is varied. Many medical researchers in large medical centers and teaching hospitals are 
technologically competent; the physicians in clinical practice, in general, lack the facilities and support 
staff required for technological innovation. The manufacturer of medical products may have a long 
and successful history of developing and marketing medical products or may be a small aggressive 
company with innovative ideas but lacking experience or resources for sophisticated device development 
and evaluation. . 
The relative importance and role of each participant depends ·on the technology gap between that par-
ticipant and the technology being transferred. It is the role of the Biomedical Applications Team to 
recognize the strengths and weaknesses of each participant and to supply the motivation, competence, 
and institutional linkages to ensure success. The methodology of the Biomedical Applications Team as 
. presented in Section 2.2 addresses these factors. 
Technology will be interpreted throughout this report as including all of the skills, techniques, and 
understanding, as well as the materials, devices, and hardware that make up a specific technology. 4 
Technology transfer as used here will refer specifically to horizontal technology transferi that is, the 
transfer of technology from one situational context--the one for which the technology was originally 
developed--to another situational context. 5 This transfer will normally result in some modification of 
the technology or in the situational context to which it is transferred. 
2.2 Biomedical Applications Team Methodology 
As noted in the introduction, and as indicated in Figure 3, the activities of the Biomedical Applications 
Team program are separated into four phases. Within each of these phases, the specific actions and 
responsibilities of the team are, to a certain extent, fixed. However, team methodology incorporates 
flexibility, which allows the team to respond appropriately to the specific characteristics of particular 
technology transfer cases. Brief descriptions of the methodologies used by the Biomedical Applications 
Team are presented in the following four sections. 
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2.2.1 Identification of Opportunities 
The identification of technology transfer opportunities involves the identification of: (1) a medical 
problem or need, and (2) relevant aerospace technology that can potentially solve the medical problem 
or satisfy the medical need. 
Medical problems are identified through the direct interaction of a team member with a researcher or 
physician within a medical institution. A study of medical technology transfer by the National Acade-
my of Engineering and funded by NASA has concluded that the recipient must take the lead in defin-
ing medical problems. (> This is consistent with the experience of the RTI team. As a result, the 
Biomedical Applications Team emphasizes obtaining complete and extensive descriptions of medical prob-
lems and needs from the problem originator or recipient. The significance of the medical problem is 
verified by the RTI team through literature reviews and interviews with manufacturers, health agen-
cies, and other clinicians. 
Certain medical institutions and medical professionals are more innovative than others. 7 Research has 
shown that the first hospitals to adopt innovation are generally large medical centers or teaching hos-' 
pitals geographically close to the place where the technology was developed. Further, those hospitals 
with highly trained medical staff tend to be more innovative. Finally, once a hospital has adopted an 
innovation, the widespread use of that innovation is enhanced if the innovating hospital interacts 
frequently with other medical institutions. The Biomedical Applications Team, in its problem identifica-
tion activities, has considered these factors. 
Because of the innovative physician's emphasis on quality, medical technology introduced in the past 
10 to 20 years has tended to increase the sophistication of medical diagnosis and treatment, but has 
not contributed to a reduction in the cost of health care. The efforts of the Biomedical Applications 
Team have been directed toward the utilization of aerospace technology to reduce or contain health 
care costs. 
Technology relevant to medical problems and needs can be identified by a variety of techniques. Once 
a medical problem or need is specified, a computerized information search of the aerospace literature 
is performed by one of the six NASA Industrial Applications Centers (lACs). The RTI team has used 
the services of the North Carolina Science and Technology Research Center located in Research Tri-
angle Park, North Carolina. Computerized information searchers can identify information on potentially 
relevant technologies. 
An additional approach to identifying aerospace technology is the circulation of problem statements to 
NASA field centers. Individual medical problems are concisely described in problem statements. Each 
problem statement is sent to NASA engineers and scientists working in areas that are related to the 
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technological aspects of the medical problem. Responses to problem statements from these engineers 
and scientists can lead to the identification of solutions. 
Finally, the Biomedical Applications Team contacts NASA scientists and engineers known to have a 
strong interest in transferring technology to medicine and known to be working in relevant technical 
areas. This is the most direct, efficient, and rapid approach to locating technology. The next phase 
of the program is the investigation of factors that .determine which opportunities are most likely to be 
successful. 
2.2.2 Screening 
Effective screening enables the RTI Biomedical Applications Team to focus on those opportunities with 
the most promise for successful medical solutions and commercial products. I n order to continue work 
on a particular opportunity, the team must determine that most of the following requirements are 
satisfied: 
The solution improves medical treatment or diagnosis or reduces the cost of health care. 
The solution .is recognized by a Federal health agency and the medical community as a 
contribution to improved health care. 
The solution incorporates NASA technology or expertise. 
The market for the new or improved medical product justifies the required capital in-
vestment and production cost to the manufacturer. 
A manufacturer can be offered sufficient market protection, either by· exclusive license 
or by lead time, to justify the required investment in product development. 
The solution represents a discrete, well-defined transfer of technology involving limited 
research and development effort. 
Candidate manufactur'ers with the required marketing' and production capabilities have 
expressed an interest in commercialization. 
These factors are evaluated by review of the biomedical literature, market surveys, interviews with 
industry representatives, and discussions with appropriate medical staff. Much of the data collected 
in this process is used in the development of commercialization strategies as described in the next 
section. 
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2.2.3 Commercialization Strategies 
The development of strategy for successful technology transfer must consider product development and 
marketing, clinical trials, FDA approval, acceptance by the medical profession, and identification of 
funding sources for the various tasks involved. Because of the emphasis on obtaining commercializa-
tion of NASA technology, strategies must involve obtaining industry participation. 
The National Academy of Engineering study of medical technology transfer referenced in the preceding 
section reached some important conclusions concerning strategy for technology transfer. 6 Successful 
technology transfer requires intimate and significant involvement of the donor and recipient through-
out the transfer process. Further, the involvement of industry throughout the transfer process is 
essential. The manner in which new technology is introduced to the medical field is a critical factor 
in successful technology transfer; the new or improved product must be accepted by and applied by 
the medical community. 
The medical technology transfer model in Figures 4 and 5 was developed by the RTI team to summarize 
the requirements for each phase of this complex commercialization process. An important lesson that 
can be taken from this model and the team1s experience is that careful planning throughout the proj-
ect is necessary for successful product development and tr·ansfer to industry. 
The experience of the RTI Biomedical Applications Team has confirmed and expanded upon these con-
clusions. Industry must be involved throughout the transfer process and must be included as early 
as possible. Further, the involvement of industry generally requires some means for giving a specific 
manufacturer a proprietary position. This may involve either an exclusive license to a patent or lead 
time to allow sudden entry of the new product into the medical market. Industry tends to view new 
product opportunities from the outside as competition with its own internally generated product ideas, 
which means that opportunities for technology transfer generated through the NASA Technology Uti-
lization Program have to compete for industry capital and management attention. These barriers can 
best be overcome by the Biomedical Applications Team through an analysis of patent positions, devel-
opment costs, and market studies, followed by careful selection of potential manufacturers. 
The acceptance of a new product by the medical community involves a fairly specific sequence of 
events. The product must be subjected to clinical trials, and the results published by a recognized 
medical expert. The product usually must be .exhibited at medical meetings. This sequence normally 
leads to physician acceptance. 
Medical marketing and distribution frequently are not necessarily an integral function of all medical 
product manufacturing firms. Thus, in addition to obtaining the participation of a medical product 
man'ufacturer, the team may· also identify and involve an organization capable of marketing and dis-
tributing those products. 
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Each specific opportunity for medical technology transfer offers a new set of barriers and strategic 
options. Thus, the formation of strategy is not a specific activity. It is in itself a problem-solving 
effort. The most important common feature of strategy formation is thoroughness; all contingencies 
must be anticipated. 
2.2.4 Implementation and Monitoring 
Experience in the implementation of strategy has shown that the chance for successful technology 
transfer is increased by active involvement of the Biomedical Applications Team throughout the trans-
fer process. By monitoring and coordinating the activities of the participants, minor problems can be 
prevented from becoming major obstacles. The RTI team prepares Project Evaluation and Review 
Technique/Critical Path Method (PERT /CPM) scheduling networks to provide systematic analysis for 
complex projects. Although these charts are too large to be included in this report, they are sent to 
the participating NASA field centers and to NASA Headquarters. 
Reports and documentation are an integral part of the team methodology; they are involved through-
out the technology transfer process. Implementation of strategy is no exception. Periodic status 
reports are issued informally to keep all participants informed. Upon completion of the transfer 
process, the team prepares a technology transfer· report documenting all important aspects of the 
transfer process. 
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3.0 COMMERCIALIZATION ACTIVITIES 
3.1 Aircraft Wheelchair: The Stowaway 
The aircraft wheelchair project at Langley Research Center has resulted in the development of a com-
mercially available wheelchair that allows movement down airplane aisles and access to onboard lava-
tories. Advex Corporation of Hampton, Virginia, is manufacturing and marketing the chair, called 
the Stowaway, for use in aircraft and other environments. United Airlines has negotiated the pur-
chase of Stowaways from Advex for use on its Boeing 767s, which are scheduled for service in the 
Fall of 1982. Other airlines have expressed an interest in using the Stowaway on their 767s and other 
planes. 
This project has involved the cooperative efforts of the following organizations: University of Virginia 
Rehabilitation Engineering Center, NASA Langley Research Center, domestic and international commer-
cial airlines, aircraft manufacturers, Rehabilitation International-USA, and the Research Triangle 
Institute Biomedical Applications Team~ Funding for the University of Virginia's participation in the 
program was provided by the National I nstitute of Handicapped Research. 
3.1.1 Background 
Airplanes are a major environmental barrier for the mobility impaired. Of the approximately 700,000 
people in the United States who rely upon wheelchairs for mobility, many experience serious profe~­
sional and social limitations as a result of their inability to use air travel. Requests from the disabled 
population and the President's Committee on Employment of the Handicapped have brought the problem 
of plane accessibility to the attention of the airlines. For example, in a 1978 purchase agreement for 
a new generation of aircraft, the Boeing 767, United Airlines requested features to make the cabins 
more accessible for the disabled and the elderly. 
In response to these requests, the Aerospace Industries Association created a special committee, the 
TARC 218-2 committee, to examine the problem of aircraft accessibility. The TARC committee, which 
included representatives from all of the commercial aircraft manufacturers, agreed to participate in 
Rehabilitation International's program, Access to the Skies. The objective of this program is to make 
the cabins of commercial ai rcraft more accessible for the elderly and the disabled. Access to the Skies 
is supported by a grant from United Technologies Corporation. Both the TARC committee and the 
Access to the .Skies program have identified the need for an onboard wheelchair as a key element in 
the entire cabin accessibility system. 
3.1.2 Development and Commercialization of the Stowaway 
The University of Virginia Rehabilitation Engineering Center was one of four groups to undertake the 
development of an onboard wheelchair. In· September 1980, Dr. Colin McLaurin, Director of the 
University of Virginia Rehabilitation Engineering Center, met· with the RTI team and Langley Research 
Center materials and structure analysis engineers to discuss cooperative projects. Dr. McLaurin 
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requested the assistance of NASA in developing an onboard aircraft wheelchair. The chair was de-
signed by Dr. McLaurin and Ted Bruning, a graduate student at the University of Virginia. 
In response to Dr. McLaurin's request, engineers at Langley optimized the design by utilizing aero-
space technology in materials and structure analysis engineering. In the early summer of 1981, Ted 
Bruning spent several weeks working with engineers at Langley Research Center. Mr. Robert Baucom, 
a NASA materials engineer, was NASA's project director for the aircraft chair. The product of this 
joint effort was a prototype onboard aircraft chair made of graphite composites. The chair, called the 
Stowaway, is shown in Figures 1-3. 
Evaluation of the Stowaway and other onboard chair prototypes has been coordinated and supported 
by the Access to the Skies program. I n the evaluation program, the Stowaway has been tested by 
Boeing, United Airlines, Pan American World Airways, Trans World Airways, Air Canada, Aer Lingus, 
British Airways, Scandinavian Airlines, and South African Airlines. Other carriers are scheduling 
participation in the evaluation program. The results of all of these evaluations will be critical to the 
airlines' selection of an onboard chair. The results received thus far from United Airlines, Aer Lingus, 
and British Airways indicate that the Stowaway performed very well and was the preferred chair among 
the designs evaluated. The other airlines are expected to complete their evaluations by February 1982. 
Advex Corporation in Hampton, Virginia, built the four prototypes of the Stowaway needed for the 
Access to the Skies evaluation program. Advex plans to continue manufacturing and marketing the 
chair for use in aircraft and other environments where a lightweight, compact wheelchair is needed. 
Commercialization of the Stowaway was coordinated by the RTI team and Mr. John Samos, Technology 
Utilization Officer at Langley Research Center. The RTI team will continue discussions with airlines' 
cabin engineering staff responsible for the selection of an onboard chair. 
3.1.3 Description of the Stowaway 
The Stowaway is a compact, lightweight folding wheelchair designed for conveying airline passengers 
from their seats to the washroom .As seen in Figure 3, the Stowaway moves easily down the narrow 
aisles of the plane. The wheelchair has 8-inch diameter wheels in the front and 4-inch diameter 
casters in the rear. This wheel pattern allows easier pushing over low sills and other obstacles with-
out forward tipping, and it also allows easier maneuvering in the washroom area. The seat of the 
wheelchair is solid for easy transfer; the back is made of vinyl fabric. The footrest folds backwards 
for transfer. Safety belts with Velcro fasteners provide restraint for the knees and torso. Parking 
brakes which lock the front wheels can be operated by an occupant or an attendant. 
The Stowaway is folded by squeezing a release located behind the seat. This allows the wheelchair to 
collapse forward into the folded position. The Stowaway is erected by grasping the crossbar at the 
top of the seat back and pulling to the upright position. A sharp snap at the end of the pull engages 
the lock. 
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The Stowaway weighs less than 15 Ibs (7 kg). Its chief features are simplicity, lightweight, and com-
pactness. As seen in Figures 1 and 2, the Stowaway folds to an 8-inch height for easy storage on a 
plane. The Stowaway is especially suitable for use in washrooms with side doors such as those in the 
new Boeing 767s. I n these washrooms, a pivot transfer permits the passenger access to the toilet from 
the wheelchair. 
3.1.4 Aircraft Wheelchair Summary 
Objective 
To design, fabricate, and evaluate a lightweight wheelchair for use in commercial aircraft. The chair 
should be compatible with aisle width, seat height, and lavatory access. 
Project Summary 
September 1980 Meeting held at Langley Research Center (LaRC) with University of Virginia (UVa) 
wheelchair researchers, Langley materials and structure analysis engineers, and 
RTI team. 
October-
November 1980 Robert Baucom (LaRC) and Doris Rouse (RTI) visited University of Virginia Reha-
bilitation Engineering Center to discuss a collaborative aircraft wheelchair project 
between UVa and NASA. 
May 1981 Ted Bruning (UVa) began summer internship at Langley to complete design and 
fabrication of aircraft wheelchair. Chair given the name "Stowaway. II 
June 1981 Composite aircraft wheelchair prototype completed. Prototype demonstrated by UVa 
and RTI team to .Fairchild Burns, Inc., Invacare Corporation, Custom Industries, 
and Advex Corporation. 
July 1981 Advex Corporation (Hampton, VA) awarded contract from Access to the Skies to 
build four UVa/NASA aircraft chairs for evaluation by airlines. 
August 1981 Composite prototype evaluation begun by Pan Am, United, Boeing, and international 
airlines. 
December 1981 Stowaway selected by United Airlines for use on their Boeing 767s. Negotiations 
begun between Advex Corporation and United on purchase of the chairs. Advex 
plans to manufacture and market the Stowaway for aircraft and other applications 
requiring a lightweight, compact chair. . 
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3.2 Parker Hannifin Biomedical Products Division 
Participation in NASA technology utilization projects initiated, by the RTI Biomedical Applications Team 
has demonstrated for Parker Hannifin Corporation the considerable potential for the development of 
new medical devices by the utilization of hydraulic systems developed for spacecraft. In April 1981, 
Parker Hannifin, a major aerospace manufacturer, announced the creation of a Biomedical Products 
Division. 
The Biomedical Applications Team acts as a catalyst and interface between aerospace technology and 
technical needs in medicine. The product of the teamls activities is, in most cases, a new or improved 
medical device made possible by the utilization of technology developed by NASA. I n the case study 
reported here, the RTI team identified NASA hydraulic control systems as a technology with especially 
promising potential for applications in medicine. Miniaturized, high reliability hydraulic control systems 
developed for use in spacecraft are sufficiently sophisticated for Use in prosthetic devices to mimic 
the body's impaired fluid control systems. RTI team projects involving NASA hydraulics technology 
have thus far resulted in: 
Prosthetic Urinary Sphincter: a device for restoring bladder control is now in animal 
testing. 
Micromed®: a portable medication infusion pump has been approved by FDA for 
marketing. 
Programmable Implantable Medication System: an implantable pump is currently in 
animal testing for insulin delivery under funding from the National Institutes of Health. 
Parker Hannifin Biomedical Products Division: a commitment to. the development 
and marketing of medical devices has been made by a major aerospace hydraulics 
manufacturer. 
3,2.1 Prosthetic Urinary Sphincter 
The Prosthetic Urinary Sphincter was Parker Hannifin's first involvement in the development of medical 
devices. In May 1976, the RTI team prepared a problem statement describing the need for a prosthetic 
hydraulic control system to allow the voluntary control of bladder function. (Loss of bladder control 
is frequently seen in spinal cord injuries, multiple sclerosis, diabetes, and postprostatectomy.) The 
RTI team identified the appropriate hydraulics technology at NASAls Marshall Space Flight Center 
(MSFC). At the suggestion of MSFC engineers, the RTI team discussed the problem with Parker 
Hannifin and other aerospace hydraulics manufacturers. These discussions led to a cost-sharing con-
tract between NASA and Parker Hannifin in 1978 to modify a hydraulic control system used in the 
Vi king lander for use in a prosthetic urinary sphincter. 
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The device, now in animal trials, is currently being developed in a collaborative effort between Parker 
Hannifin, Medical Engineering Corporation, and Rochester General Hospital. Collaboration between 
these three organizations in the development and testing of the prosthetic urinary sphincter has led 
to the development of two additional implantable devices that utilize the same hydraulic control system: 
a sphincter to allow the patient to open and close an ileostomy or colostomy, and a hydraulic penile 
prosthesis. Animal and clinical trials for these devices are expected to begin in 1982. 
3.2.2 Micromed® 
The application of Parker Hannifin's hydraulics technology to the problem of continuous infusion of 
medication has resulted in the development of an electronically controlled, automatic medication i~usion 
pump capable of delivering volumes as small as 1 millionth of a liter. This device, the Micromed , was 
approved by the FDA in November 1981 for human use. Marketing of the device, developed in a 
collaborative effort between Parker and Pacesetter Systems, will begin in January 1982. 
This project began with the preparation of a problem statement by the RTI team in 1977 describing 
the need for a portable infusion pump to allow the constant delivery of medication and the attainment 
of a steady therapeutic level of medication in the body. (A pump of this type would be most bene-
ficial in the management of diseases such as diabetes, thalassemia, and hormone disorders where fre-
quent injections are required.) Before preparing the problem statement, the RTI team interviewed 
researchers funded by the National I nstitutes of Health to develop a pump of this type. These 
researchers indicated that NASA's technology in miniaturized hydraulic control systems had the poten-
tial for solving some of the probl.ems they had encountered in the development of a reliable, portable 
system. To facilitate Parker's development of a portable medication infusion device, the RTI team 
arranged a meeting between the Parker project engineer, an NIH-funded researcher at the Carnegie-
Mellon Institute of Research, and an RTI team member to review the status of current research in this 
area and to define optimal device specifications. 
/'3.2.3 Programmable Implantable Medication System 
The Programmable Implantable Medication System (PIMS) is being developed at Johns Hopkins Univer-
sity Applied Physics Laboratory under the direction of Robert Fischell. Goddard Space Flight Center 
has provided the overall project management. The PIMS is an implanted device that can be pro-
grammed by a physician after implantation to deliver a 24-hour cyclic profile of medication. I n addi-
tion, the physician can tailor as many as six different delivery profiles for patient self-medication. 
The PIMS keeps a record of the medication volume delivered by the pump. The physician can com-
municate with the implanted device via telephone transceivers to check function and delivery profile. 
This device can be useful in the treatment of diabetes, intractable pain, hypertension, and hormone 
disorders. 
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The PIMS incorporates NASA technology in three areas: (1) microminiaturized hybrid circuitry; 
(2) command and telemetry systems similar to those used in small, astronomy satellites and other 
spacecraft; and (3) miniature, high reliability hydraulic control systems. During the early develop-
ment of PIMS, the RTI team worked closely with Applied Physics Laboratory and NASAls Marshall 
Space Flight Center to identify the appropriate technology and manufacturer for the hydraulic control 
system. The RT I team met with representatives from Applied Physics Laboratory and Parker Hannifin 
Corporation in May 1979 to discuss Parkerls participation in the project. Parker Hannifin has subse-
quently developed the hydraulic portion of the PIMS and plans to manufacture this component for the 
commercial units. Pacesetter Systems, Inc., will manufacture the electronic components and market 
the PIMS. Animal trials for the PIMS delivery of insulin for diabetes are in progress under funding 
from the National I nstitutes of Health. Human implants are scheduled for 1982. 
3.2.4 Parker Hannifin Biomedical Products Division 
Participation in these projects ( Figures 1-3) sponsored by NASAls Technology Utilization Program 
demonstrated to Parker Hannifin the commercial potential for medical devices incorporating sophisti-
cated hydraulic control systems originally developed for the space program. A recent article in 
Parker Hannifin's corporate publication, Parker World (I ssue 6, Summer 1981), described the creation 
of the Biomedical Products Division and the devices currently under development. This article is 
presented below: 
Parker Targets New Biomedical Frontier· 
Using technologies developed in our Aerospace Group, Parkerls newly created 
Biomedical Products Division is currently testing devices which may revolutionize 
the treatment of a number of diseases .. 
At an April press conference in· Cleveland, Pat Parker announced our Company's 
official entry into the biomedical field, taking technology "from outer space to 
inner space"--the human body. 
Bill Webster, Aerospace Group vice president and general manager of the new 
Division, pointed. out that the transfer of technology to this newest frontier 
requires Parker engineers to draw on the knowledge gained from developing mini-
ature fluid systems for manned and unmanned space vehicles. For example, in 
Viking's search for life on Mars, it was Parkerls latching solenoid valve, the 
smallest ever to fly in space, which controlled the injection of precise amounts of 
nutrient into the Martian soil samples. 
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Parker's first biomedical project was started over three years ago. It is the 
development of an inwardly inflatable cuff with a pressure regulation system 
smaller than a nickel, which will be implanted in the body to control urinary 
incontinence. This system, developed in conjunction with NASA and the Rochester 
General Hospital of Rochester, New York, is currently being tested in animals and 
is expected to be tested in humans next year. 
The project has now been expanded to include the use of the inflatable cuff to 
aid people with colostomies and ileostomies. These systems will be undergoing 
animal testing this fall. 
The next biomedical project, started over two years ago, is an electronically con-
trolled, automatic· medication infusion pump, designed to deliv~Minjection amounts 
as small as one millionth of a liter. One pump, the Micromed ,smaller than a 
business card and about 5/8 inch thick, can easily be concealed under clothing. 
The other, being developed in conjunction with the Applied Physics Laboratory of 
Johns Hopkins University, is designed to be implanted in a manner similar to a 
. heart pacemaker. 
Both of these pumps will be used .in the improved treatment of diabetes, hormone 
disorders, cancer, mental illness, intractable pain, drug addiction and alcoholism. 
There are 1,500,000 insulin dependent diabetics, 300,000 new terminal cancer 
patients every year and 750,000 mental patients under drug therapy. These 
people could all benefit from the Parker system which releases minute amounts of 
medication, as required, rather than occasional massive doses with possible 
attendant side effects. 
The most recent biomedical program is an advanced method of blood plasma therapy 
developed by Dr. Nose and his associates at the Cleveland Clinic. The system, 
which removes undesirable constituents in the blood, has shown great promise in 
the treatment of rheumatoid arthritis, lupus, myasthenia gravis and other autoim~ 
munediseases. 
Pat Parker, while observing the experimental treatment system at the Clinic, sug-
gested to Dr. Nose that Parker's aerospace technology could be employed to 
improve the system and make it suitable for broad application in many hospitals. 
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The Biomedical Pr9ducts Division built the first unit, called Cryomax TM, last fall 
and now has six additional units undergoing testing. Official Food and Drug 
Administration (FDA) clinical trials are underway at the Cleveland Clinic and Rush 
Presbyterian Hospital in Chicago, and will soon commence at Cedars Sinai in Los 
Angeles. Successful completion of these tests this fall should result in FDA 
approval for broader application early next year. 
With these major projects underway, Parker is committed to providing a significant 
contribution to the biomedical field. Pat Parker has noted that "it is a natural 
transfer of aerospace fluid system technology. The human' body is a complex of 
interacting fluid systems. Each fluid system requires precise control of flow, 
pressure, temperature and contamination. Only in the last 20 years has control 
technology approached the sophistication of the human body. II 
Bill Webster commented that IIcomponents for space craft and devices designed for 
implantation in the human body have similar technological requirements. Both 
require that the devices be small, lightweight, highly, reliable and precise and be 
capable of eXisting in a hostile environment. II 
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4.0 SPECIAL PROJECTS 
4.1 Cerebrospinal Fluid Control System: Phase 0 Study 
NASA is considering the development and clinical testing of a cerebrospinal fluid (CSF) control system 
under joint sponsorship with the National I nstitutes of Health (N I H) and industry. The proposed 
system would improve the management of hydrocephalus, an abnormal accumulation of cerebrospinal 
fluid in the central nervous system. A major goal of the new system would he to reduce the number 
of necessary reoperations and, thus, reduce health care costs and patient risks. The project will 
consist of three major phases: (1) a Phase 0 study, (2) a prototype development phase, and (3) clin-
ical trials. NASA's involvement will be limited to the first two phases. 
In August 1981, NASA asked the RTf team to conduct the Phase 0 study for the CSF control system 
under the direction of the Langley Research Center Technology Utilization Office. The objective of 
this study is to develop the information required by NASA for a decision on whether to proceed with 
the CSF control system development program. The decision to proceed will be based upon: demon-
stration of a significant need for a CSF shunt system, identification of potentially applicable NASA 
technology, consensus on design goals by clinicians and researchers, and cost-sharing commitments 
by N f H and industry. To obtain this information, the RTI team has planned the Phase 0 study as 
three tasks. 
Task 1: Define the Medical Problem and the State of the Art in CSF Shunts 
This task will be accomplished by a thorough literature review as well as by interviews with 
neurologists, neurosurgeons, and members of the medical device industry, NIH, and the 
Food and Drug Administration (FDA). The Task 1 study report will contain product sheets 
on commercially available systems and concise descriptions of ongoing research and develop-
ment. Failure modes and limitations of available systems will be identified and presented. 
The optimum operating characteristics and configuration of a new CSF shunt will be devel-
oped and specified .. The etiology of conditions leading to the need for CSF shunt systems 
will be summarized with disease incidence data. 
Task 2: Determine Engineering Feasibility of Design Concepts 
Functional design concepts will be based upon data obtained in Task 1. Concepts for the 
pressure transducer, the command/telemetry ·system, and the hydraulic design will be devel-
oped with the participation of subcontractors with design expertise in these areas. All items 
of NASA technology that will be incorporated in the CSF shunt system and supporting docu-
mentation will be identified and presented in the Task 2 study report. 
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Task 3: Prepare Project Plan for Development of Improved Shunt 
A project plan will be developed that includes the following elements. Items of hardware 
that must be developed will be specified. A modified PERT chart with approximate cost will 
be prepared; critical or pacing elements and the critical path will be identified. FDA 
requirements for data and guidelines that apply to clinical trials will be specified and incor-
porated in the overall plan and PERT chart. Appropriate manufacturers for the shunt· 
system will be developed and presented. Overall program costs will be estimated and a com-
plete strategy for funding both the CSF system development project and clinical trials will 
be generated. NASA, NIH, and industry will be included in this strategy, with roles being 
dependent on organizational missions, policies, and objectives. 
Task 1 has been completed with the exception of interviews with CSF shunt manufacturers, which are 
expected to take place in early January 1982. . A brief summary of the Task 1 results is presented 
below. The complete Task 1 study report will be available in February 1982. At that time, NASA 
Headquarters, Langley Research Center, and the RTI team will decide whether the results support 
proceeding with Task 2, Determine Engineering Feasibility of Design Concepts. 
4.1.1 Literature Review 
The first activity of the RTI team in the Phase 0 study was a thorough review of the relevant litera-
ture. Topics included in this study were: CSF physiology, hydrocephalus etiologies and management, 
shunt design, valve design, intracranial pressure monitoring, shunt failure modes, and methods for 
assessment of cerebrospinal fluid dynamics in patients. 
CSF Physiology and Pathology 
Hydrocephalus is an abnormal accumulation of cerebrospinal fluid within the ventricles of the central 
nervous system. These ventricles are fluid-filled chambers that support and protect the brain and 
spinal cord. Cerebrospinal fluid is normally produced at a rate of approximately 0.35 mL per minute 
or about 504 mL· per day. The CSF volume is 50 mL in infants and 150 mL in adults. The CSF, 
therefore, is renewed completely every 8 hours. 
The principal production site is the choroid plexus of the ventricular system, especially in the lateral 
ventricles. The CSF flows from the lateral ventricles to the third ventricle and caudally to the fourth 
ventricle, from which it passes to the subarachnoid space surrounding the brain and spinal cord. 
The CSF is reabsorbed into the venous blood at the arachnoid villi. These pathways for cerebrospinal 
fluid flow and reabsorption are illustrated in Figure 1. These pathways are particularly vulnerable to 
obstruction at certain narrow sites as a result of developmental or acquired disorders. 
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CEREBROSPINAL FLUID CONTROL SYSTEM 
MAJOR PATHWAYS OF CEREBROSPINAL FLUID FLOW, 
SAGITTAL VIEW (A) AND LATERAL VIEW (B) 
VALVE 
THOMAS H. MILHORAT, M.D., HYDROCEPHALUS AND THE CEREBROSPINAL FLUID, 
BALTIMORE: THE WILLIAMS AND WILKINS CO., 1972. p. 25. 
Figure 1 
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Hydrocephalus resulting from a blockage .of the pathways, preventing flow of CSF to the reabsorption 
sites, is called obstructive or noncommunicating hydrocephalus. If the CSF circulates freely but the 
absorption sites are impaired, then the condition is classified as communicating hydrocephalus. Both 
communicating and noncommunicating hydrocephalus can be congenital or acquired. For example, 
communicating hydrocephalus can result from a head injury with subsequent subarachnoid hemorrhage. 
The hemorrhage impairs the reabsorptive ability of the arachnoid villi. Noncommunicating hydro-
cephalus can result from the growth of a cyst or tumor or from any inflammatory swelling, causing an 
obstruction in the CSF pathway to the reabsorption sites. In rare cases, hydrocephalus can result 
from the overproduction of CSF by the choroid plexus. I nfantile hydrocephalus (all cases diagnosed 
in the first 3 months of life) outnumbers the cases of acquired hydrocephalus by approximately 3 to 1. 
The most common clinical feature of infantile hydrocephalus is enlarging head size accompanied by 
vomiting and irritability. The dilated ventricles and increased intracranial pressure can lead to retar-
dation of motor development, generalized spasticity, and impaired cognitive abilities. 
Incidence of Hydrocephalus 
As indicated in the preliminary market study, liThe Potential Market for an lon-Textured Hydrocephalus 
Shunt, II which was conducted for NASA by ECON, Inc., the reported incidence of hydrocephalus varies 
widely. A major factor in this variance is that hydrocephalus is often secondary to other diseases 
(spina bifida, intracranial hemorrhage) and, thus, is often unreported in statistical records of hospital 
diagnoses. The Fact Sheet: Hydrocephalus, published by the National Institute of Neurological and 
Communicative Disorders and Stroke, estimates the prevalance of hydrocephalus in the following 
paragraph: 
Hydrocephalus at birth occurs in more than 1 of every 1,000 live births; approximately 4,200 
infants annually are born with hydrocephalus in the United States. Another estimated 6,000 
children develop "hydrocephalus during the first 2 years of life from complications of other 
conditions. Adults can also develop hydrocephalus from injury or disease. 
The Spina Bifida Association of America reports that over 11,000 children are born with spina bifida 
(cleft spine) in the United States each year. The Association estimates that 70 to 80 percent of these 
children develop hydrocephalus. Interviews with manufacturers should provide an estimate for the 
number of adults requiring a CSF shunt for the management of hydrocephalus resulting from head 
injury, tumor, meningitis, or intracranial bleeding. 
Current CSF Shunting Techniques 
The three most successful treatments for hydrocephalus are: 
pathway, (2) insert intracranial shunts to bypass a blockage 
to other body cavities by the use of extracranial shunts. 
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(1) remove the lesion blocking the CSF 
of the pathway; or (3) divert the CSF 
Where possible, the direct removal of the lesion is the preferred treatment. 
potential for relieving the hydrocephalus and restoring normal CSF flow to 
Unfortunately, it is seldom possible to remove the obstruction because the 
infection is too diffuse or is in a location inaccessible for safe removal. 
This procedu"re has the 
the reabsorption sites. 
tumor, hemorrhage, or 
I ntracranial shunts may be used to bypass the obstruction by providing a pathway from the ventricular 
system to the subarachnoid space. The success of this procedure depends upon the normal functioning 
of the reabsorption sites, the arachnoid villi. 
Extracranial shunting of the CSF is used in communicating hydrocephalus and in cases of noncommuni-
eating hydrocephalus where the obstruction cannot be removed or bypassed by an intracranial shunt. 
Most hydrocephalus patients are treated with an extracranial shunt. The two sites most often used 
for drainage of the CSF from the ventricle are the right atrium of the heart (ventriculoatrial) or the 
peritoneal cavity (ventriculoperitoneal). Placement of a ventriculoatrial shunt is illustrated in 
Figure 2. 
Most commercial extracranial shunting devices consist of three components: the ventricular catheter, 
a reservoir for flushing this catheter, and the distal catheter for drainage. In shunts draining into 
the atrium; a one-way flow valve is necessary to prevent backflow of blood into the catheter. In some 
cases, a double reservoir is used to allow intraventricular injection of chemotherapy agents and anti-
biotics. A wide range of set pressures, flow rates, and antisiphoning features are available for 
selection by the surgeon. 
Shunt Complications " 
An estimated 50 percent of hydrocephalus patients will require at least one reoperation to repair or 
replace a malfunctioning shunt. The distal catheter, in most cases, must be replaced several times to 
compensate for growth of the child. 
Obstruction of either the ventricular or distal catheter is the major cause of shunt failure. The 
resulting inadequate drainage produces elevated ventricular pressures. I n the ventricular catheter, 
the blockage is caused by glial cells and astrocytes and/or ingrowth of the choroid plexus. In 
ventriculoatrial shunts, distal obstruction is usually" caused by the formation of an adherent thrombus 
on the atrial catheter. "Ventriculoperitoneal shunts usually become obstructed distally as a result of 
patient growth or formation of a peritoneal cyst. Ventriculoperitoneal shunt complications are summar-
ized in Figure 3. 
The complication of overdrainage of CSF from the ventricle may result in ventricular collapse or 
hemorrhage. 
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A recent study, II An I nvestigation of Cerebrospinal Fluid Shunt Valves, II conducted for the Food and 
Drug Administration investigated shunt valve construction, testing, and labelling. Most CSF shunt 
manufacturers categorize their valves by closing pressure and offer the surgeon three to four ranges 
to be selected according to the patient1s requirements. Several investigators, however, have found 
significant variance in flow characteristics of valves labeled at the same pressure range. Performance 
of a valve at too low a closing pressure can result in overdrainage of the ventricle. Standardized 
valve testing methods for quality control and uniform labeling are suggested in the FDA report. An 
American Society for Testing and Materials standards committee is currently addressing these same 
issues. 
Significant morbidity and mortality of hydrocephalus patients, especially those with ventriculoatrial 
shunts, is caused by infection. Strict aseptic surgical techniques have been suggested as the most 
effective means of preventing this complication. Antibiotic impregnated silicone is currently being 
investigated for use in hydrocephalus shunts. 
4.1.2 Interviews 
The interviews with neurosurgeons, NIH researchers, and FDA representatives on the CSF control 
system were conducted by the RTI team and two consultants active in hydrocephalus research, 
Dr. Anthony Marmarou of the Albert Einstein College of Medicine Department of Neurologic Surgery 
and Dr. Richard Johnson of the University of North Carolina Department of Biomedical Engineering. 
The resulting hypothetical CSF control system is illustrated in Figure 4 and described below. The 
physiological objective of the proposed device is to maintain the cerebrospinal fluid compartments at 
normal volume and pressure. The design features of the proposed system are as follows. 
1. Sensor for measurement of ventricular volume. 
2. Sensor for measurement of intraventricular pressure. 
3. Sensor for measurement of flow through the catheter. 
4. Microprocessor control of flow rate profile for 24-hour cycle based on input volume, 
pressure, and flow data. 
5. Capability of manual override and external control of flow rate. 
6. Capability of program modification by physician using transceiver communication to 
readjust flow rate, profile, threshold volume, and pressure. 
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7. Capability of remote transmission of operating characteristics to central facility using 
transceiver communication. . 
8. Alarm for abnormal pressure, volume, or increased catheter resistance. 
9. Bidirectional flow capability with pump reservoir for programmable retrograde flushing 
of ventricular catheter and outflow part. 
10. Compensation for transient pressure increases resulting from coughing, sneezing, and 
change in hydrostatic level. 
11. Self-contained power pack with provision of external recharge. 
12. Fail-open configuration with remote alarm. 
The following individuals have been interviewed by the RTI team and Drs. Marmarou and Johnson. 
Robert Munzner, Ph.D. 
Food and Drug Administration 
Bureau of Medical Devices 
Bethesda, MD 
Fred Epstein, M.D. 
Department of Neurological Surgery 
New York University Medical Center 
New York, NY 
Luis Schutt, M.D. 
Department of Neurosurgery 
Children's Hospital of Philadelphia 
Philadelphia, PA 
Harold Portnoy, M.D. 
Oakland Neurological Clinic 
Oakland, CA 
Thomas Milhorat, M. D. 
Children's Hospital National Medical Center 
Washington, D. C. 
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T. Hambrecht, M.D. 
National I nstitute of Neurological and Communicative Disorders and Stroke 
Bethesda, MD 
Gerald Hochwald, M. D. 
Department of Neurosurgery 
New York University Medical Center 
New York, NY 
K. Shapiro, M.D. 
Albert Einstein College of Medicine 
Department of Neurological Surgery 
New York, NY 
A. B. Butler, M.D. 
University of Virginia School of Medicine 
Department of Neurosurgery 
Charlottesville, VA 
John Jane, M. D. 
University of Virginia School of Medicine 
Department of Neurosurgery 
Charlottesville, VA 
R . Woosley, M. D. 
University of North Carolina School of Medicine 
Department of Neurosurgery 
Chapel Hill, NC 
Drew Sullivan, M.D. 
University of Kentucky School of Medicine 
Department of Neurosurgery 
Lexington, KY 
The following questions were included in each interview: 
1. Do you think this system has clinical application? In what class of patients? 
2. Do you agree with the physiological objective of normal volume at normal pressure? Do 
you think it could be a pressure-only system? 
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3. Are the following desirable features: retrograde flushing, manual override, program-
ming for a 24-hour cycle? 
4. Would this system best be used as, an assist device for currently available shunts or as 
a new shunt system in itself? 
5. What is the most reasonable implant site? 
6. What is the maximum size tolerated? 
7. What is the minimum requirement for battery longevity? 
8. I s a rechargeable system acceptable? 
9. What catheter features should be incorporated to compensate for growth? 
10. What other features in the system would be useful? 
A summary of each interview wi II be included in the final report for the Phase 0 study. I n general, 
the neurosurgeons were quite enthusiastic about a system of this type. Several offers were made for 
assistance in developing and evaluating the device. A representative from the NIH felt that 
microprocessor-controlled CSF shunts would probably be the way of the future, but that current 
transducer technology. (pressure, volume) would be ,the weak link in the implementation of the proposed 
system. . 
4.1.3 Action 
The RT I team and its consultants will complete the interviews with manufacturers and other NIH 
researchers in January 1982. The complete report on Task 1 of the Phase 0 study will be submitted 
to NASA Langley Research Center and NASA Headquarters in February 1982. A decision on whether 
to proceed with Task 2 will be made by NASA at that time. 
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4.2 AAMI Standards Development for Medical Devices 
The Association for the Advancement of Medical Instrumentation (AAMI) coordinates the development 
of standards for medical devices. The standards are drafted by committees comprised of individuals 
representing many different interests in the health care field, including manufacturers, physicians, 
surgeons, nurses, engineers, medical technologists, and representatives from government regulatory 
agencies. During the past year, the RTI team has explored the possibility of worl<ing with these 
standards committees as a more efficient method for the identification of technical requirements consid-
ered significant by clinicians, researchers, manufacturers, and regulatory agencies. 
4.2.1 Standards Development Process 
There are four phases of approval in the process of developing 
standard, (2) the proposed standard, (3) the final standard, 
Standard. 
an AAMI standard: (1) the draft 
and (4) the American National 
The draft standard is the first step in the standards development process. It represents the efforts 
of a small working group and is designed to identify the important operating characteristics and pos-
sible hazards of a particular family of medical devices. Safety and performance guidelines are estab-
lished and included in the draft standard. The draft standard serves as an initial framework for the 
construction of a true· standard. Its purpose is to promote response from concerned users and manu-
facturers to improve the draft standard before advancing it to further stages in the development 
process. The draft standard may go through substantial revisions during this phase and, therefore, 
should not be used for any purpose other than as a basis for review and discussion. 
The proposed standard is the second phase in the development process. A draft standard is consid-
ered a proposed standard after approval by a formal written vote from the originating AAMI technical 
committee. (The committee is composed of 20 to 50 people representing various professions in health 
care, government, and device manufacture.) It is distributed once again for review and comment to 
refine it even further. The proposed standard is still subject to extensive revision ~ and like the draft 
standard, should not be used for any purpose other than as a basis for review and discussion. 
The final standard is a proposed standard that· has been reviewed and approved by both the orlQI-
natingAAMI technical committee and the AAMI Standards Board. By the time a standard reaches this 
phase it has been carefully reviewed by many individuals inpatient care and industry. Any objections 
have been resolved to the satisfaction of the originating committee and the Standards Board. Resolu-
tion does not always mean the addition or deletion of requirements to the standard, but simply that 
the objections were reviewed further and responded to accordingly. The final standard is considered 
to be in the form necessary for submission to the American National Standards Institute (ANSI). Any 
major change(s) to the content of the standard at this stage dictates its return to the originating 
committee and its status reverts to a draft or proposed standard, depending on the extent of the 
change(s) . 
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The final standard is sent to ANSI after it has been approved by the originating AAMI technical 
committee and the AAMI Standards Board. At ANSI, the standard receives final review. Upon satis-
factory completion of all the compulsory requirements and procedures, the final standard is designated 
as an American National Standard. It can now be used by industry, government, and the health care 
community as a basic safety and performance guideline for a specific medical device. 
4.2.2 RTI Biomedical Applications Team Activity 
The RTI team developed a new problem statement this year as a result of working with one of the 
standards committees. The team was asked to identify a method to detect the dislodgement of the 
temperature control probe from an infant's skin while the infant is in an infrared radiant warmer. A 
dislodged probe can cause incorrect temperature feedback to the warmer's control system, which can 
lead to serious burns to the infant. The Biomedical Applications Team's involvement stemmed from 
comments made during the review of the Draft Standard for Infant Radiant Warmers. The draft called 
for a dislodgement detection capability. The manufacturers responded that the technology to meet the 
request was not available. The RTI team distributed a problem statement to the NASA field centers. 
A solution suggested by a Lewis Research Center engineer has been distributed to the members of the 
standards committee for review. If NASA technology can be utilized, the draft standard will retain 
the dislodgement detection requirement and will perhaps result in the use of the NASA-developed tech-
nology on all infant radiant warmers. . 
4.2.3 Transfer Opportunities 
In working with AAMI on this. problem, the RTI Biomedical Applications Team uncovered new avenues 
for technology transfer. The draft standard may recommend a safety or performance feature that will 
greatly improve a device's safe, ·efficient operation. The manufacturers may contend, however, that 
current methods would make their costs ·prohibitive. In such cases, NASA technology may provide 
the answer with either a new technology or a more efficient, low-cost alternative. 
Potentially the most rewarding aspect of working with AAMI standards lies in the establishment of con-
tacts during the investigation of specific problems. The first action usually taken by a Biomedical 
Applications Team member, after learning of a problem from an AAMI representative, is to interview 
key members of the AAM I standards committee for the device in question. These people usually have 
diverse backgrounds, representing industry, medicine,research, etc., and, therefore, can present 
the problem from several viewpoints. I n addition·, other opportunities for Biomedical Applications Team 
activity may develop during discussions with committee members. Some of the individuals are medical 
device manufacturers, in which case the door has been opened on commercialization sources for team 
projects. Discussions with a manufacturer can reveal industrywide problems ancf/or problems with 
products on which there is no AAMI activity. 
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The interviews provide an excellent opportunity to disseminate information on the function and capabil-
ities of a NASA Biomedical Applications Team. The active conversation allows instantaneous response 
to the detailed questions surrounding a team1s operation and its role in technology transfer. The 
result should be a boost to team productivity, since the "consumer" will be aware of the services 
available and seek them out in the future. 
4.2.4 Conclusions 
The process of developing· a medical device standard brings together medical researchers, doctors, 
designers, marketers, regulatory agencies, and others. Problems of both manufacture and use are 
discussed openly,· and capabilities and ideas shared. This type of situation can only have a positive 
effect on the performance .and safety of medical devices. The involvement of the Biomedical Applica-
tions Team with the standards development process should provide an efficient method for the transfer 
of aerospace technology to meet significant medical needs. Figure 1 summarizes the standards 
development process and the interaction of the NASA Technology Transfer Program. 
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4.3 Composite Materials Walker: Market Study 
Many disabled individuals with limited ambulatory capability can obtain the upright support and stabil-
ity necessary for ambulation by the use of an aid known as a walker. This device is a four-legged, 
three-dimensional frame within which the patient stands. Ambulation is assisted by the use of arm 
strength in much the same manner as arm crutches. Most wal kers are fabricated from aluminum with 
steel tubing at the stress points. They normally weigh between 2.7 and 3.6 kg (6-8 Ibs) and are 
designed to fold for storage behind a car seat or in a truck. 
As the RTI team concluded in a previous study on the market for composite orthotics and prosthetics, 
. the aluminum and stee~ walkers currently available are entirely adequate for a large segment of the 
patients using walkers; In the present study, the RTI team's objective was to define the patient 
population that could benefit from a more lightweight walker and to define the manufacturing and mar-
keting factors critical to its commercial feasibility. The focus of the study was a prototype walker of 
composite graphite fiber/epoxy resin designed and built by Dr. Ernie Harrison of Mississippi Methodist 
Rehabilitation Center. Dr. Harrison did this work as part of a Langley Research Center contract 
entitled II Applications of Advanced Composite Materials to Orthotic Devices." 
4.3.1 Description of Graphite/Epoxy Walker 
The walker built by Dr. Harrison .is shown in the figure on page 55. All components of the walker 
are graphite/epoxy. The top horizontal tube between the two side panels is made in two sections to 
permit folding. Each section of the horizontal tube is attached to the upper horizontal tube of each 
side panel by a modified right-angle connector that is free to rotate on the horizontal tube of the side 
panel. A large-diameter sliding graphite/epoxy tube slides into place to lock the two-piece horizontal 
bar into a rigid unit for the operational configuration. Dr. Harrison's wal ker prototype folds to a 
thickness that is several inches less than commercially available walkers, resulting in easier storage 
behind a car seat or in the home. The graphite/epoxy walker weighs 1.93 kg (4.25 Ibs), which is 
1.25 to 1.47 kg (2.75-3.25 Ibs) less than available aluminum and steel walkers. Dr. Harrison's 
wal ker, therefore, offers advantages in weight reduction, portability, and storage. 
4.3.2 Patient Population for Lightweight Walker 
According to Dr. Harrison, the occasional user of a wal ker who has reasonable upper arm strength 
and upper body control has little difficulty with currently available walkers. The two classes of 
patients in which the weight of the walker is a problem are the very active patient and the severely 
disabled patient. The active patient uses a walker to assist in maintaining a normal lifestyle, which 
includes several daily transfers in and out of an automobile. The use of a lightweight wal ker would 
reduce the patient's required daily energy expenditure. The smaller folded thickness and reduced 
weight would make the storage of the wal ker in the backseat of an automobile a much easier task. 
The second category of patient, the severely disabled, would be able to ambulate more frequently with 
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a lightweight wal ker. Many of these patients are arthritic with mUltiple joint involvement, and have 
severe pain upon movement and little strength. A reduction in walker weight could make a significant 
difference in the frequency and ease of ambulation for these patients. 
To explore further the potential uses of Dr. Harrison's walker, the RTI team demonstrated the proto-
type to Mr. Breur at Preston Corporation, a major distributor of walkers and other rehabilitation aids. 
Mr. Breur was enthusiastic about Dr. Harrison's walker. He felt that the significantly lighter weight 
would be especially important for elderly patients. He also pointed out that the composite walker is 
more durable than the aluminum devices, which are easily dented or bent. This aspect would be 
important for wal kers used by very active patients and for those used in institutional envi ronments. 
For marketing purposes, Mr. Breur suggested changing colors and rounding corners to improve the 
aesthetic appearance of the wal ker. 
4.3.3 Manufacturing and Marketing Considerations 
To evaluate the manufacturing and marketing factors critical to the commercialization of the lightweight 
wal ker, the RT I team interviewed the wal ker manufacturers and graphite composite materials suppliers 
indicated in Table 1. In all of the interviews, the increased cost of the graphite/epoxy composite 
materials over aluminum was the most critical factor for commercialization. Lumex Corporation, a major 
walker manufacturer, estimated a market of 100 ,000 lightweight walkers per year. Commercial plas~ics 
were investigated by Lumex as a low-cost alternative to graphite composite materials, but were found 
to lack the necessary strength for this use. Lumex indicated that the cost of manufacturing the cur-
rent aluminum walkers is approximately $12 per walker. If the composite walker is to be commercially 
feasible, then the manufacturing costs should not be greater than $12. 
Cost is such a critical factor because most walkers are purchased under third-party reimbursement 
systems such as Medicare. These reimbursement systems use established standard allowances for 
walkers and will not authorize a higher reimbursement rate for a more lightweight walker. This cost 
constraint was emphasized by Lumex, Preston, and I nvacare, another major wal ker manufacturer. The 
issue of cost constraints and third-party reimbursement was a major factor in the RTI team's earlier 
study on the use of prosthetics and orthotics. 
The two options for resolving the problem of the higher cost for the composite materials are (1) to 
change Medicare policy to allow a higher reimbursement rate for the lightweight walker or (2) to 
utilize more inexpensive composite materials in the walker. The RTI team's discussions with Social 
Security personnel indicated that the first option was a remote possibility. The RTI team, therefore, 
investigated the use of less expensive materials by interviewing composite material suppliers. 
J. R. Haracz of Union Carbide estimated that the lowest price for their PAN (polyacrylonitrile) fiber 
would be $15 per pound, if ordered in very large quantities. In terms of the manufacturing cost of 
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$12 for the 4-pound chair, however, the materials cannot exceed $3 per pound. Mr. Haracz suggested 
using a blend of graphite, Du Pont1s Kevlar ($7/lb), and glass fibers ($0.80/lb) in the walker to 
reduce costs. The glass would provide body, the Kevlar would provide impact resistance, and the 
graphite, strength. Dr. James Leslie at the Advanced Composite Pipe and Tube Company suggested 
using composite materials only in the walker's tubes and using aluminum for the other components. 
He also suggested using Kevlar rather than 100 percent graphite for economic and safety reasons. A 
broken graphite tube often results in sharp protrusions while a Kevlar tube will break like a green 
stick. Du Pont, however, has suggested blending Kevlar with another fiber to obtain the compression 
characteristics required for the walker. A Kevlar/graphite blend ratio of 70:30 'was suggested. The 
cost for materials and fabrication of the walker's tubes using this blend would be $9.80. The cost of 
the aluminum corners and the horizontal tube would be approximately $4 per walker. With appropriate 
design considerations, the assembly cost could' be minimal--an estimated $1 per walker. The total 
manufacturing cost of this walker, therefore, would be $14.80. 
4.3.4 Status and Action 
The materials and manufacturing options developed in this study have been presented to the walker 
manufacturers. Lumex is conducting a study to estimate the market for a walker at this price. The 
team will continue discussions with the walker manufacturers. In addition, the team will continue 
dialogue with the materials suppliers so that lower cost carbon fibers currently being developed will 
be considered as ,materials for lightweight wal kers. 
4.4 References 
1. Biomedical Applications Team. Applications of Aerospace Technology in Biology and Medicine, 
Final Report, January 1, 1979-April 15, 1980. Prepared by Research Triangle Institute, Research 
Triangle Park, N. C., for the National Aeronautics and Space Administration, Hampton, Virginia. 
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TABLE 1. COMPOSITE WALKER INTERVIEWS 
Mal Mixon, president 
Donald E. Karl, 
Vice President of Operations 
Invacare Corporation 
Elyria, Ohio 44035 
Guardian Products 
N. Hollywood, CA 91605 
Mr. Charles Murcott, President· 
Mr. Coviello, Marketing Manager 
Lumex, Inc. 
Bayshore, New York 11706 
Mr. Breur 
Preston Corporation 
New York, NY 10003 
Dr. James Leslie 
Advanced Composite Pipe and Tube 
Santa Anna, CA 
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Mr. J. R. Haracz 
Union Carbide 
Chicago, IL 
Mr. H. P .. Bodenstab 
Du Pont Company 
Wilmington, DE 
Bill Martin 
Hercules Corporation 
Washington, DC 
Social Security Administration 
Washington, DC 
Mr. Ted Green 
U.S. Manufacturing 
Pasadena, CA 
5.0 STATUS OF ACTIVE TRANSFER PROJECTS 
COMPOSITE MATERIAL APPLICATIONS 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Many orthotic devices can be improved by reducing their weight. However, weight reduction must 
not be accompanied by a reduction in the strength of the material. 
Solution 
NASA has demonstrated the feasibility of utilizing carbon fiber composites in the fabrication of a wide 
variety of objects, from satellite dish antennas to automobile fenders. In many instances, the same 
technology can be applied to dramatically reduce weight and yet retain strength in orthotic devices or 
mobility aids. . 
NASA Technology 
Although the price of the composite material has fallen, the fabrication of composite devices remains a 
prime obstacle. Flat or gently curved pieces are reliable and fairly easy to produce. However, most 
orthotic applications involve tubular members, pivot joints, and T and L joints of tubular members, 
and require slight bending of these components to achieve a custom fit. The technology for forming 
these configurations with composite material does not yet rival that of such metals as steel or alumi-
num. NASA has funded an RTOP to study the development of biomedical applications and the develop-
ment of the material processes to achieve reliable fabrication of orthotic devices. 
Principals 
Mr. Robert M. Baucom, Material Applications Branch, NASA Langley Research Center, Hampton, 
Virginia. 
Ms. Sheila T. Long, Technology Utilization Office, NASA Langley Research Center, Hampton, Virginia. 
Dr. Ernest Harrison, Director of Biomedical Engineering, Mississippi Methodist Rehabilitation Center, 
Jackson, Mississippi. 
Cost to NASA 
This is a 3-year project funded under an RTOP for $45,700. 
Commercialization Strategy 
Under funding from Langley Research Center, Dr. Harrison developed a walker by using a technique 
for joining T and L joints from composite tubing. The RTI team recently completed a study of the 
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marketing and manufacturing factors critical to the. commercialization of the composite walker. The 
results of this study can be useful in the identification of medical and rehabilitative devices in which 
the higher cost of composite materials would not be a critical factor. 
Status 
Dr. Harrison is developing new fiberglass/graphite/epoxy structures and structural mechanics analyses 
techniques for evaluation of their potential use in prosthetic devices and other aids such as wheel-
chairs. 
Action 
The RTI team will continue to assist Dr. Harrison in the identification of potential manufacturers and 
in the evaluation of marketing factors critical to the commercialization of prosthetic devices fabricated 
from composite materials. 
54 
COMPOSITE MATERIAL APPLICATIONS 
• REDUCE WEIGHT OF BRACES, PROSTHETIC 
DEVICES, WHEELCHAIRS, WALKERS, ETC. 
• SEEK MEDICAL APPLICATIONS Of NASA-
DIVELOPED COMPOSITE- MATERIALS AND 
RELATED MANUfACTURING TECHNIQUES 
• WEIGHT SAVINGS Of AT LEAST 5O(M) 
• MISSISSIPPI METHODIST REHABILITATION 
CENTER, JACKSON 
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DETECTION OF A DISLODGED TEMPERATURE PROBE 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
I nfant radiant warmers are widely used in hospital delivery rooms and nurseries to maintain the correct 
body temperature of newborn babies. These devices, which radiate energy in the far infrared spec-
trum, are servocontrolled via a single patient temperature probe that attaches to the infant's skin. If 
the probe becomes dislodged or is improperly applied, the warmer may deliver excess radiation to the 
infant who may in turn experience overheating, respiratory distress, dehydration, and other serious 
complications. 
Solution 
Currently available radiant warmers contain alarm circuits that are activated if the infant's temperature 
does not meet preset temperature limits. A system is needed to sound the alarm if the probe is dis-
lodged or improperly positioned. 
NASA Technology 
A solution from Lewis Research Center recommended the utilization of both the selfheating properties 
and the passive temperature sensing capabilities of thermistors for the detection of a dislodged temper-
ature probe. 
Principals 
Dr. Richard Ariagno, Neonatology, Stanford Medical Center, California. 
Mr. Tim Davis, Product Safety Engineer, Ohio Medical Products, Madison, Wisconsin. 
Cost to NASA 
No cost is anticipated. 
Commercialization Strategy 
Some of the companies interviewed indicated a desire to incorporate a dislodgement alarm if it were a 
low-cost addition. The FDA is developing a standard for infant radiant warmers. 1 The Association 
for the Advancement of Medical Instrumentation (AAMI) Standards Committee is considering the addition 
of such a dislodgement sensor to its list of requirements for infant radiant warmers. 2 
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Status 
A detailed explanation of the proposed NASA technology solution to the problem has been mailed to 
the AAMI Standards Committee members and to several manufacturers of infant warmers. One letter 
of reply advises the RTI team that this type of technology is being considered for incorporation in a 
proprietary device. 
Action 
Upon request, followup assistance in the implementation of the technology will be given to recipients 
of the proposed solution. 
References 
1. U.S. Food and Drug Adminstration. Development of a Standard for Infant Warmers and Incuba-
tors, PB-263250. National Technical l.nformation Service, Springfield, Virginia. 1977. 
2. Association for the Advancement of Medical Instrumentation. Standard for I nfant Incubators. 
AAMI 11-08/80, Arlington, Virginia. 
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DETECTION OF A DISLODGED 
TEMPERATURE PROBE 
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DETECTION OF A DISLODGED 
TEMPERATURE PROBE 
• AlARM SYSTEM TO PREVENT OVERHEATING DUE TO 
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• ASSOCIATION FOR THE ADVANCEMENT OF MEDICAL 
INSTRUMENTATION 
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FIBER OPTICS SYSTEM FOR KNEE SURGERY 
BA Team Personnel: Dr. H. Clark Beall 
Problem 
A variety of surgical procedures within the knee joint can be performed·, without opening the bursa, 
by watching the surgical implements on closed-circuit TV. In such procedures, an arthroscope probes 
the inside of the knee joint and a TV camera presents the image. However, the arthroscope is prone 
to break because it must be rigidly connected to the camera. Also, the TV camera must be draped 
with sterile covers because it is so close to the surgical zone. 
Solution 
These problems have been described to optics engineers at NASA Langley Research Center, who recom-
mend that the arthroscope be interfaced to the TV camera by a coherent fiber optics cable. Such a 
cable would allow the TV camera to be placed outside the sterile zone. 
NASA Technology. 
Coherent fiber optics technology is most commonly utilized within NASA in the design of nondestructive 
test, measurement, or inspection instruments. 
Principals 
Dr. R. B. Caspari, orthopedic surgeon, St. Mary's Hospital, Richmond, Virginia. 
Mr. David Rhodes, NASA Langley Research Center, Hampton, Virginia. 
Mr. John Franke, NASA Langley Research Center, Hampton, Virginia. 
Dr. F. H. Bassett, Orthopedic Surgeon, Duke University, Durham, North Carolina. 
Cost to NASA 
Local funds are being utilized at NASA Langley Research Center for work on interfacing the fiber 
optics viewing cable with the TV camera and the arthroscope. 
Commercialization Strategy . 
After minor problems with the fiber optics system have been corrected, the RTI team will direct its 
efforts toward promoting the commercialization of the ·device. 
Status 
The first prototype of the fiber optics viewing system was criticized on aesthetic grounds for exhibiting 
too much "fishnet" masking of the image. Arrangements have been made for a second evaluation of 
the prototype by Dr. Bassett of Duke University. 
Action 
The prototype will be delivered to Duke University in January 1982. The evaluation should require 
less than 2 months. 
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FLOW SENSOR FOR AN INFUSION PUMP 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
An infusion pump system is required that has a flow control superior to any similar device on the mar-
ket. The system would be particularly useful in clinical applications where long-term infusion at well-
controlled, low flow rates are necessary. 
Solution 
A key component would be a flow sensor that could provide a feedback signal to the pumping mecha-
nism. 
NASA Technology 
Mr.' Eugene Win kler of the Johnson Space Center has designed a new flow sensor that is suitable for 
measuring the rate of injection of intravenous biomedical fluids. The device is described in NASA Tech 
Briefs, Fall 1980, page 335. A disclosure of new technology has been filed on the device. 
Principals 
Mr. Eugene Winkler, Wastewater Quality Monitor Systems, Johnson Space Center, Houston, Texas. 
Mr. Jack Wheeler, Technology Utilization Office, Johnson Space Center, Houston, Texas. 
Dr. William Clingman, marketing consultant. 
Cost to NASA 
No cost is anticipated. 
Commercialization Strategy 
The RTI team has contacted several medical device manufacturers regarding commercialization of the 
ffow sensor. As a result, inquiries about licensing the sensor have been received from three com-
panies currently marketing infusion pumps. 
Status 
At least three serious inquiries from manufacturers have been received concerning the licensing of this 
technology. Negotiations have stalled on the question of exclusive licensing. 
Action 
The RTI team will continue to support efforts toward the commercial development of this device and 
resolution of the licensing question. 
63 
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FLOW SENSOR FOR AN INFUSION PUMP 
HYDROCEPHALUS SHUNT--VENTI LATION 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Hydrocephalus is a condition in which the cerebral ventricles enlarge abnormally when the pressure of 
the cerebrospinal fluid rises. To relieve this pressure, surgeons implant a shunt to drain the excess 
fluid into other cavities of the body. The shunt frequently fails because the inlet is blocked by an 
ingrowth of choroid plexus or an accumulation of cellular or fibrin debris. 
Solution 
A multi -ended inlet catheter, with hundreds of tiny inlets formed by ion-etching techniques, could 
minimize this problem. The small holes would inhibit tissue ingrowth, and the multiplicity of holes 
would reduce the possibility of blockage .. 
NASA Technology 
Technology developed in NASAls Ion Propulsion Engine Program is being used to perforate small-
diameter catheters. 
Principals 
Mr. Bruce A. Banks, Ion Beam Applications Section, NASA Lewis Research Center, Cleveland, Ohio. 
Mr. Eugene Pawlik, Jet Propulsion Laboratory (JPL), Pasadena, California. 
Dr. Eldon Foltz, University of California, I rvine, California. 
Pudenz-Schulte Medical Research Corporation, I rvine, California. 
Cost to NASA 
An RTOP totaling $123,000 was submitted in 1978. First-year funding of $41,000 was approved. ' An-
other $5,000 was allocated to get the opinions of other medical experts before beginning the second 
year of the project. A $40,000 feasibility study on 2- to 20-micron pores was conducted by JPL in 
1981. NASA has allocated $80,000 to continue this JPL effort in 1982. 
Commercialization Strategy 
Pudenz-Schulte Medical Research Corporation, a manufacturer of ventricular catheters, has been con-
tracted by NASA-Lewis to develop an ~mimal model for evaluation of the Lewis prototypes and to con-
duct bench tests for flow studies. Other commercial interests and FDA will be informed of the results 
on the shunt system as they are available. 
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Status 
JPL technical staff has formed 15 micron holes in a Teflon shunt. Refinements in the ventilating tech-
nique are being investigated. 
Action 
Development of ventilation techniques will continue. Flow testing will begin in 1982. Dr. Foltz and 
. JPL plan to submit a joint proposal to the National I nstitutes of Health in June 1982 for the continued 
development and evaluation of the ion thruster ventilated shunts. 
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IMPLANT MATERIALS TESTING 
BATeam Personnel: Dr. James N. Brown, Jr. 
Problem 
Many design and fabrication aspects of metallic surgical implants result in local regions of high stress 
where defects can exist or develop durinQ use. The need to improve the reliability of these pros-
thethic devices has been well documented. 1 '2 3 
Solution 
More effective screening procedures for metallic prosthetic devices could improve the mechanical reli-
ability of these implants. 
NASA Technology 
Fracture control methods (material qualification, design, and inspection), which were developed by 
NASA for screening critical spacecraft hardware, can be applied to metallic implants. NASAls proce-
dures for evaluating the impact of a liquid environment on mechanical reliability would be especially 
applicable. 
Principals 
Mr. Robert E. Johnson, Vice President, Eagle Engineering, Inc., Houston, Texas. 
Mr. Don Chwirut, Bureau of Medical Devices, Food and Drug Administration, Washington, DC. 
Mr. Edward Mueller, Bureau of Medical Devices, Food and Drug Administration, Washington, DC. 
Cost to NASA 
NASA funded a feasibility study to evaluate the application of aerospace fracture control methods to 
surgical implants. This study, conducted by Eagle Engineering, Inc., cost $19,000. FDA has trans-
ferred $50,000 to Langley Research Center to support the continuation of Eagle Engineeringls work to 
improve implant design and testing. 
Commercialization Strategy 
The Eagle Engineering study and additional work will result in the establishment of FDA guidelines 
for product certification and device test protocols to be used by implant manufacturers. 
Status 
In discussions with the RTI team, the FDA strongly recommended that NASA investigate the applica-
tion of aerospace materials evaluation techniques to surgical implants. FDA is interested in incorpo-
rating NASA technology in the Bureau of Medical Devices l fracture control program. Eagle Engineering 
completed a feasibility study under NASA funding in June 1981. Following a favorable review of the 
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results, FDA transferred funds to Langley Research Center for continuation of the study to improve 
implant design and testing. 
Action 
The FDA/NASA study on implant materials will continue. FDA is providing the materials and implant 
samples from Eagle's study. Sheila Long at Langley Research Center will monitor the Eagle Engineering 
contract. Eagle will be using Langley's electron microscope for surface studies. The fracture control 
methods developed in this study may be incorporated in commercial manufacturing and quality control 
procedures for implanted devices. 
References 
1. Weinstein, A., H. Amstutz, G. Pavon, and V. Franceschini. Orthopedic Implants--A Clinical and 
Metallurgical Analysis. Journal of Biomedical Materials Research, 4:297-325, 1973. 
2.. Hench, L. L. Biomaterials. Science, 208:826-831, May 23, 1980. 
3. Hench, L. L. Future Developments and Applications of Biomaterials: An Overview. Biomaterials, 
Medical Devices, and Artificial Organs, 7(2):339-350, 1979. 
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LOW-COST UV OPTICAL DOSIMETER 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
If the radiation of the sun is permitted to strike exposed areas of skin on a daily basis over long 
periods of time, radiation of the UVB region can contribute to skin cancer. A low-cost personal 
dosimeter system is needed to quantify the total exposure of persons to UVB during their daily activi-
ties. 
Solution 
Engineers at the NASA Langley Research Center have devised a small UVB dosimeter that can be wOl'n 
unobtrusively on clothing or on eyeglasses. 
NASA Technology 
The device utilizes three items of technology: a miniature photosensor for detecting light, a miniature 
electrochemical cell for recording the radiation dosage, and an optical filter for detecting only the UVB 
region's radiation. 
Principals 
Dr. Peyton Weary, University of Virginia School of Medicine, Charlottesville, Virginia. 
Dr. Ian MacConochie, NASA Langley Research Center, Hampton, Virginia. 
Mr. R. Adams, NASA Langley Research Center, Hampton, Virginia. 
Cost to NASA 
Discretionary funds at· Langley Research Center have been used for the assembly of prototype dosime-
ters. 
Commercialization Strategy 
Inductron Corporation, Grafton, Virginia, indicated an interest in marketing the UV dosimeter for con-
sumer and agricultural use. The RTI team will continue discussions with Inductron Corporation to 
facilitate commercialization. 
Status 
Although several prototypes performed satisfactorily, a wide variance was found in the performance of 
a set of 10 dosimeters that were assembled from commercial components. The problem seemed to be 
the slight variation in the optical filters. A decision has been made to measure total UV, which is a 
much larger signal. The detectors do not vary as much in response to total UV as they do to UVB. 
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University of Cincinnati researchers have obtained a license from the Langley Research Center Patent 
Office for the modification and use of the dosimeter in research applications. University of Florida 
personnel have built several copies of the dosimeter. 
Action 
Mr. King of the NASA Langley Research Center Patent Office has pointed out that quite a few inquiries 
about licensing the dosimeter have been received. He routinely issues letters of permission for various 
governmental agencies to build, modify, and use the dosimeter. The RTI team and the Langley 
Technology Utilization Office wi" continue discussions with Inductron on the commercialization of the 
dosimeter. 
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MICROWAVE THERMOGRAPHY 
BATeam Personnel: Dr. H. Clark Beall, Dr. Michael McCartney 
Problem 
Conventional thermography us~s infrared frequencies (>10 GHz) to detect breast cancer. However, 
this technique can only detect thermal profiles at the skin's surface. Subsurface thermal anomalies, 
such as those produced by certain cancerous growths, are indirectly measured as sources of heat that 
affect the thermal profile at the surface. The inability to' measure the subsurface thermal profile 
. directly is a significant drawback of infrared thermography because: (1) surface and subsurface ele-
ments in the measured thermal profile cannot be differentiated and (2) thermal dispersion seriously 
degrades the spatial resolution needed to detect heat sources buried beneath the surface. 
Solution 
Microwave thermography can be thought of as a low-frequency analog of infrared thermography. A 
shift to lower frequencies permits detection of thermal profiles up to several centimeters below the 
body's surface. Microwave instrumentation is needed for the high spatial resolution detection of sub-
surface temperature anomalies that are typical of cancerous growth. 
NASA Technology 
Engineers at Langley Research Center have considerable experience and expertise in microwave re-
search resulting from studies on microwave energy propagation in condensed media. 
Principals 
Mr. Ken Carr, Microwaves Associates, Inc., Burlington, Massachusetts. 
Dr. John o. Buckley, NASA Langley Research Center, Hampton, Virginia. 
Veterans Administration Hospital, Hampton, Virginia. 
Cost to NASA 
The funds committed to this project total $32,500 over 2 years. 
Commercialization Strategy 
A manufacturer of microwave instrumentation is currently participating in the project. 
Status 
The NASA-owned microwave radiometer has been recently renovated at the factory. The performance 
of this radiometer will be compared to the performance of the radiometer owned by the VA hospital at 
Hampton, Virginia. 
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Action 
When the VA hospital team submits its protocol for testing the radiometer to the NASA Langley 
Research Center, the NASA radiometer will be loaned to the hospital for testing. 
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NONINVASIVE LUNG DIAGNOSIS 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Disabling pulmonary illnesses may develop as a result of occupational and environmental factors, pul-
monary vascular pathology, cystic fibrosis, asthma, or cigarette smoking. Early detection and accurate 
diagnosis of these illnesses give the treatment a greater chance of success. 
Solution 
A technique to record and analyze human respiratory sounds would make possible the detection of vari-
ations in the caliber of the airways and, thus, the early detection of pulmonary dysfunction. 
NASA Technology 
NASA research in aeroacoustics has provided a basis for a theory of the origin of human respiratory 
sound derived from the motion of vortices in the human lung. This theory has been supported by 
preliminary tests on lung models by the Medical College of Virginia and Langley Research Center. 
Principals 
Dr. Jay C. Hardin, Theoretical Acoustics Branch, NASA Langley Research Center, Hampton, Virginia. 
Dr. John L. Patterson, Jr., Medical College of Virginia, Richmond, Virginia. 
Mr. John E. Wootten, President, B&K Instruments, Inc., Cleveland, Ohio . 
. Cost to NASA 
NASA FY80 funds designated for this project totalled $61,000. The Medical College of Virginia has 
allocated $15,000 from the Hundley Fund to support this work. In addition, an NIH Research Career 
Award supports Dr. Patterson1s time on the project. B&K Instruments, Inc., has already contributed 
Mr. Wootten's consulting time during several trips to the Medical College of Virginia. 
Commercialization Stretegy 
B&K Instruments, Inc., has written to John Samos, TUO, Langley Research Center, indicating their 
interest in this diagnostic system as a commercial product. They predict a market for the system in 
employee industrial checkup centers, as well as in hospitals. B&K and the Medical College of Virginia 
will continue to collaborate on this project. 
Status 
Results of this work have been published in the following: 
Hardin, Jay C., and John L. Patterson, .Jr. Taking Soundings of the Lungs. Airways, 4(1),1979. 
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Hardin, Jay C. Noise Calculation on the Basis of Vortex Flow Models. NASA Tech Brief LAR-12271, 
Spring 1978. 
Hardin, Jay C., and John l. Patterson, Jr. Theory of Sound Generation in the Human Lung. Pre-
sented at the Mid-Atlantic Conference on Bio-Fluid Mechanics, Blacksburg, Virginia, August 10-12, 
1978. 
Hardin, Jay C., and John L. Patterson, Jr. Monitoring the State of the Human Airways by Analysis 
of Respiratory S. und. ACTA Astronautica, 6(9), September 1979. 
Hardin, Jay C. I and John L. Patterson, Jr. The Pressure Flow Realation in Bronchial Airways on 
Expiration. Presented at the Mid-Atlantic Conference on Bio-Fluid Mechanics, Blacksburg, Virginia, 
May 5-7, 1980. 
Hardin, Jay C., and John L. Patterson, Jr. Genesis of Breath Sounds: Theory and Application. 
Presented at the Fifth International Conference on Lung Sounds, London, England, September 15-16, 
1980. 
Hardin, Jay C., and John l. Patterson,- Jr. Genesis of Breath Sounds: Theory and Application. 
Presented at the Federation of American Societies for Experimental Biology, 65th Annual Meeting, 
Atlanta, Georgia, April 12-17, 1981. 
Aclion 
The soundroom as well as the acoustic and flow measurement instrumentation have been installed at 
the Medical College of Virginia. Animal and human testing will continue in the next quarter at the 
Medical College of Virginia. Flow visualization studies will continue at Langley. 
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NONINVASIVE LUNG DIAGNOSIS 
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OPHTHALMIC SCREENING DEVICE 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
Amblyopia is a childhood eye disease that affects approximately 4 percent of the population in the 
United States. It is defined as poor vision, despite correction with glasses for any refractive problem. 
I f amblyopia is detected early and then corrected, no permanent vision damage results. Therefore, 
experts recommend at least two vision tests for children before age seven. Such vision tests could 
also identify other eye dysfunctions. 
Solution 
Most children have 20/20 vision; a screening test is needed to identify the 10 percent who have vIsion 
problems. The screening test should be simple and quick due to the limited attention span of pre-
school children. With this in mind, an ophthalmologist has devised a photographic test procedure that 
records the color image reflected from human eyes in response to a. flash of light. This red IIretinal 
reflex" is occasionally observed in color flash photography when the' subject gazes directly at the cam-
era the instant the flash occurs. 
NASA Technology 
An ophthalmologist has identified an optical correlator from Marshall Space Flight Center as a device 
that could be used to quickly analyze the color photographs produced by such a screening test. The 
correlator must be modified somewhat to perform satisfactorily in the new application. An RTOP was 
submitted for FY80 to accomplish this task . 
. Principals 
Mr. Joseph H. Kerr, President, Electro-Optics Consultants, Inc., Huntsville, Alabama. 
Dr. S. Hutson Hay, ophthalmologist, Huntsville, Alabama. 
Dr. Bob Jayroe, NASA Marshall Flight Center, Alabama. 
Cost to NASA 
Marshall Space Flight Center has granted a no-cost 6-month contract extension on a $20,000 contract 
with Electro-Optics Consultants, Inc. (EOC), for the production and evaluation of a prototype screen-
ing device. EOC and Dr. Hay have invested $100,000 in the prototype development and evaluation. 
Commercialization Strategy 
An ophthalmologist representing the Dallas school system visited EOC and Marshall Space Flight Center 
in November 1981 for a demonstration of the ophthalmic screening device. The Dallas school system 
has subsequently sent a purchase order to EOC for a device to be used in the Dallas schools for 
routine screening. 
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Status 
One hundred and seventy-five students of the Alabama School for the Deaf received manual eye exam-
inations and photographic screening examinations with the NASA camera system by staff members of 
the Alabama School of Medicine at Birmingham. The photographic screening identified 23 students with 
defective retinal reflex. Subsequent manual examinations of these students by Dr. Hay revealed 22 
with various visual defects. The final report for the first part of the contract to EOC has been 
delivered to Marshall Space Flight Center. 
Action 
Dr. Hay will follow up on inquiries received after his description of the screening system at the 
Southern Ophthalmological Association meeting at Mobile, Alabama, in November 1981. Marketing 
efforts will intensify in 1982. 
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PORTABLE COOLING SYSTEM FOR QUADRIPLEGICS 
BATeam Personnel: Dr. Doris Rouse 
Problem 
Quadriplegics are vulnerable to heat stress because they cannot perspire below the level of injury, a 
condition that results from the interruption of autonomic neural pathways that mediate thermoregula-
tory perspiration and vasomotion. Quadriplegics exposed to even moderately high temperatures risk 
hyperventilation, increased heart rate, and heat stroke. 
Solution 
A portable cooling garment would eliminate these risks, thus opening new employment and daily living 
opportunities for individuals previously confined to temperature-controlled environments. 
NASA Technology. 
Technology from the development of thermal control garments to protect astronauts has been used to 
make a water-cooled vest for quadriplegics. 
Principals 
Dr. Bill Williams and Ms. Pat Kirk, Environmental Control Research Branch, NASA Ames Research 
Center, Moffett Field, California. 
Dr. Tom Krouskop, Director, Rehabilitation Engineering Center, Texas I nstitute for Rehabilitation and 
Research (TIRR), Houston, Texas. 
Cost to NASA 
Fabrication of prototype vest systems for evaluation by T I R R cost NASA $15,000. The cost to the 
National Institute of Handicapped Research (NIHR) for the evaluation at TIRR will be $20,000. 
Commercialization Strategy 
Palm Beach Medical Corporation, who has expressed an interest in marketing the quadriplegic cooling 
vest, is following the evaluation at TI R R. Other manufacturers will be contacted as well. 
Status 
Personnel at Ames Research Center designed a small water-cooling and pumping unit as well as a vest. 
An informal evaluation of the system by a quadriplegic indicated that the system was quite effective. 
TI R R will evaluate the vest in environmental chambers and in normal outpatient use. The systems have 
been delivered to T I R R and volunteers have been recruited for participation in the study. 
Action 
Funding delays at TI R R and liability questions have prevented the start of the vest evaluation. The 
RTI team is working with TIRR and Ames Research Center to resolve these issues in the next quarter. 
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PORTABLE COOLING SYSTEM FOR QUADRI lEGICS 
" QUADRIPLEGICS UNABLE TO PERSPIRE 
BELOW LEVEL Of INJURY. VULNERABLE TO 
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UNIT 
• TEXAS INSTITUTE OF REHABIUTA HON AND 
RESEARCH, HOUSTON 
Portable cooling system. A = reservoir, B = battery, 
80 C = pump. 
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Impaired Sweating Capacity," J. Appl. Physio/. 37, 1974, p. 346. 
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PROGRAMMABLE IMPLANTABLE MEDICATION SYSTEM 
BATeam Personnel; Dr. Doris Rouse 
Problem 
A number of chronic diseases require long-term infusion or frequent injections of medication. An im-
planted pump has been used for the continuous, intravenous infusion of heparin in patients for more 
than 24 months. One million diabetics in the United States depend on daily insulin injections to help 
control blood sugar levels; one in 10 of these is a child. 1 A programmable implantable pump capable 
of several delivery rates would be extremely useful in the Infusion of insulin to treat diabetes. A more 
reliable control of blood sugar levels throughout a diabetic's life is thought to diminish the incidence 
of the complications associated with diabetes--kidney disease, diabetic retinopathy, atherosclerosis, 
and heart attacks. 2 3 4 
The conventional treatment for controlling blood sugar levels in the diabetic requires two to four insu-
lin injections daily. I n addition, the patient must accept significant lifestyle and diet restrictions. 
Despite these efforts, however, true normalization of blood glucose is rare, because of changes in daily 
activity levels, changes in diet, and shortcomings in the insulin delivery system. 
Plasma glucose concentration in healthy subjects remains between 70 and 120 mg/dL over a 24-hour 
period. 4 In contrast,· a patient with juvenile-onset diabetes, who is taking multiple, daily insulin· 
injections, will still have a hyperglycemic plasma glucose concentration of more than 200 mg/dL. The 
diabetic may also experience periodic hypoglycemia (plasma glucose less than 50 mg/dL). 5 Tamborlane 
et al. recently reported that good plasma glucose control could be obtained in juvenile diabetes patients 
by the use of a portable insulin infusion system that delivers a basal rate of insulin with a prepran-
dial pulse. 6 An implantable infusion system that could achieve the plasma glucose control demonstrated 
in this external system would have obvious advantages. 
Solution 
An implantable infusion pump that could accurately deliver medication at programmed rates would have 
great potential in the treatment of several diseases including diabetes, leukemia, and thalassemia. 
Safety features and reliable delivery rates would be required to insure safe medication ·Ievels. 
NASA Technology 
The programmable implantable medication system (PIMS) will incorporate NASA technology in three 
areas; (1) Microminiaturized hybrid circuitry will be used for the pump system as well as the pro-
gramming unit. (2) The· programming unit wi.1I use command and telemetry systems with functions sim-
ilar to those used on small, astronomy satellites and other spacecraft. (3) Aerospace technology in 
miniature, highly reliable hydraulic control systems will be used in the medication delivery portion of 
the system. 
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Principals 
Mr. Robert Fischell, Applied Physics Laboratory, Johns Hopkins University, Laurel, Maryland; 
Mr. AI Mann, Pacesetter Systems, Inc., Sylmar, California. 
Mr. Steve Wirtz, Parker-Hannifin/Biomedical Products Division, I rvine, California. 
Dr. Christopher Saudek, Johns Hopkins University, Baltimore, Maryland. 
Mr. Don Friedman, Technology Utilization Officer,. Goddard Space Flight Center. 
Cost to" NASA 
An FY80 RTOP from Goddard Space Flight Center was approved for $150,000, with $950,000 in pro-
jected costs for the next 3 years. A Marshall Space Flight Center FY80 RTOP was approved for 
$75,000, with projected costs of $135,000 over the following 2 years. In March 1980, management of 
the hydraulic control RTOP was tran.sferred to Goddard Space Flight Center. The projected cost shar-
ing for the project is listed below: 
National Institute of Child Health and Human Development 
GTE 
National Institute of Arthritis, Diabetes, and Digestive and 
Kidney Diseases (NIADDKD) 
Pacesetter Systems," Inc. 
Parker-Hannifin, Inc. 
Applied Physics Lab 
Baker Foundation 
Total cost sharing 
Commercialization Strategy 
Pacesetter Systems and Parker-Hannifin plan to manufacture and market the PIMS. 
Status 
$ 400,000 
500,000 
2,500,000 
2,000,000 
1,500,000 
50,000 
2,500 
$6,952,500 
NIADDKD funding· for animal and" clinical trials of PIMS for insulin delivery began in January 1981. 
The National I nstitute of Child Health and Human Development has allocated $400,000 for evaluation of 
PIMS in the management of hormonal deficiencies. 
In October 1981, Dr. Christopher Saudek implanted a PIMS for insulin delivery in a dog that had been 
made diabetic by pancreatectomy. The pump's telemetry, programming," interrogation, patient pro-
gramming unit and timing systems" had worked well for 3 weeks. Obstruction of the catheter by 
fibrous tissue and an electrical problem necessitated .removal of the pump 25 days after implantation. 
On examination of the unit after explant, the electrical problem was found to be a minor problem 
related to prototype fabrication methods. 
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Action 
Studies on biocompatability of alternate catheter materials are being conducted by Dr. Saudek in an 
attempt to solve the problem of fibrotic reaction to the catheter and the resulting obstruction of flow. 
A second' dog implant is scheduled for mid-February 1982. If the remaining animal implants are suc-
cessful, the first human implant is scheduled for late 1982. The RTI team will participate in the PIMS 
working group meeting at APL on February 25-26,1982. 
References 
1. Schapiro, George A. Medical Electronics, p. 55, June 1979. 
2. Cahill, G. F., Jr., O. D. Etzweiler, and N. Freinkel. New England Journal of Medicine, 
294: 1004, 1976. 
3. Siperstein, M. D. New England Journal of Medicine, 296: 1060, 1977. 
4. Service, F. J., et al. Diabetes, 19:644, 1970. 
5. Molnar, G. D., Taylor, F. W., and A. L. Langworthy. Mayo Clinical Proceedings 47:709-719, 
1972. 
6. Tamborlane, W. V., et al. New England Journal of Medicine, 300(11):573-578, March 15, 1979. 
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PROSTHETIC URINARY SPHINCTER 
BATeam Personnel: Dr. Doris Rouse 
Problem 
A malfunctioning urethral sphincter is often responsible for the inability to control emptying of the 
bladder. This condition may result from congenital, traumatic, postsurgical, or neurogenic disorders. 
Continence can sometimes be restored by an implanted device that occludes the urethra and allows vol-
untary voiding by manual release of the occluding pressure. Two factors currently prevent widespread 
acceptance of such devices by the medical community: (1) the surgical complexity of the implantation 
procedure and (2) a high rate of device malfunction, often the result of valve failure. 
Solution 
A simpler, more reliable system is needed for occluding the urethra. 
NASA Technology 
The low-pressure, "zero" leakage, high-reliability valves used in the Viking project have been adapted 
for use in a prosthetic urinary sphincter. 
Principals 
Mr. John B. Tenney, Department of Surgery, Rochester General Hospital, Rochester, New York. 
Mr. Steven Wirtz, Parker Hannifin Corporation, Irvine, California. 
Mr. Dave Sanders, President, Medical Engineering Corporation, Racine, Wisconsin. 
Cost to NASA 
NASAlS total cost was $203,000. Parker Hannifin Corporation has invested $250,000. Medical Engi-
neering Corporation (MEC) has invested $250,000. In-kind contributions by Rochester General Hospital 
(RGH) have totaled $25,000. 
Commercialization Strategy 
MEC will market and distribute the system worldwide. Parker Hannifin will supply the hydraulic con-
trol portion of the system. MEC and Parker Hannifin are currently developing two other medical 
devices that utilize the NASA valve developed by Parker Hannifin. 
Status 
Problems encountered in the manufacture of the polysulfone valves have been resolved. Valves for 
animal testing were delivered to MEC in November. Although the valves performed to specification, 
the flexibility characteristics of the reservoir material resulted in inadequate maintenance of pres-
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sure in the system. Design and material changes to overcome this problem were discussed at a 
. November 30, 1981, meeting in Racine, Wisconsin. 
Action 
To solve the pressure maintenance problem, the reservoir material will be changed by MEC. Formal 
animal trials are now expected to begin in March 1982 and human implants to begin in December 1982. 
MEC will be responsible for coordinating the clinical trials and obtaining FDA approval. 
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TEXTURING FOR PERCUTANEOUS CONNECTORS 
BATeam Personnel: Dr. Doris Rouse 
Problem 
'Percutaneous connectors are conduits through the skin that facilitate the transmission of fluids or 
connecting devices between the external environment and the body's internal milieu. Current percu-
taneous connectors are unacceptable for long-term implants because of externalization and infection. 
,Solution 
I f percutaneous connectors could be developed with a reduced tendency to externalize and with an im-
proved body fluid seal to inhibit bacterial invasion, morbidity could be greatly reduced arid new device 
applications could be explored. 
NASA Technology 
NASA electron propulsion technology may be used to ion-beam texture percutaneous connectors to pre-
vent externalization and reduce infection. 
Principals 
Mr. Bruce Banks, NASA Lewis Research Center, Cleveland, Ohio. 
Dr. George Picha, President, Applied Medical Technology, Inc., Lakewood, Ohio. 
Cost to NASA 
An FY80 RTOP was submitted for $155,000 over a 3-year perio'd. Cost sharing by the potential manu-
facturer will be $252,000 over 4 years. 
Commercialization Strategy 
A NASA patent disclosure has been filed. Applied Medical Technology, Inc., plans to market textured 
connectors if the study proves successful. 
Status 
In September, Applied Medical Technology, Inc., submitted the first annual report on the NASA Lewis 
Research Center contract to evaluate surface morphologies for percutaneous connectors. This study 
demonstrated that a regular array of micropillars can inhibit epithelial downgrowth and subsequent 
rejection of the percutaneous connector. Consistent and reproducible success of this morphology is, 
however, limited by other variables such as surgical technique, 'tissue mechanics, and postoperative 
care. 
Action 
The contract with Applied Medical Technology will continue through 1982. 
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PERCUTANEOUS CONNECTORS 
II) PREVENT INFECTION AND REJECTION OF 
THROUGH-THE-SKIN CONDUITS 
• TEXTURE SURFACE OF CONDUIT MATERIAL 
FOR TISSUE ATTACHMENT 
• NASA-LEWIS ION-BEAM TECHNOLOGY 
• APPLIED MEDICAL TECHNOLOGY, INC. 
CLEVELAND, OH 
Scanning electron micrograph of ion-beam textured surface 
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TEXTURING SURFACES FOR CARDIOVASCULAR PROSTHESES 
BATeam Personnel: Dr. Doris Rouse 
Problem 
The ideal vascular prosthesis should promote the formation of a stable, nonthrombogenic blood inter-
face. A material with this property would be useful for heart replacements, as heart-assist devices, 
and in vascular applications. 
,Solution 
Studies have shown that a surface with a microstructure will produce a thin, uniform, and well-
nourished neo-intima, or layer of blood components and cells. A thin neo-intima is desirable because 
it Is less thrombogenic. The thickness of the neo-intima that develops on a heart-assist device bladder 
is directly related to the height of the pillars texturing the surface. Present mold-manufacturing tech-
nology limits this pillar height to a minimum of 250 IJm. A technique to produce shorter pillars on 
the material may produce a thinner, less thrombogenic neo-intima. 
NASA Technology 
'NASA electron propulsion technology can be used to make materials with smaller pillar heights. 
Principals 
Mr. Bruce Banks, NASA Lewis Research Center, Cleveland, Ohio. 
Thermo Electron Corporation (TECO), Waltham, Massachusetts. 
National Heart, Lung and Blood Institute (NHLB I), Bethesda, Maryland. 
Cost to NASA 
An FY80 RTOP for $133,000 over 3 years was funded. Cost sharing by NHLBI and TECO will be 
$119,000. 
Commercialization Strategy 
Successful ion-beam texturing would improve the vascular prostheses currently on the marl<et as well 
as heart-assist devices, when they are available. Manufacturers of vascular prostheses will be pre-
sented with the results of this work on heart-assist pump bladders. 
Status 
NHLBI has cofunded a joint effort between TECO and NASA Lewis Research Center to fabricate six 
ion-textured bladders for left ventricular assist devices. This work complements an NHLB I-funded 
project at the University of Utah entitled IIDevelopment and Evaluation of Textured Surfaces. II Under 
a contract from NASA Lewis Research Center, Diecast Dies, Inc., textured the mandrils and formed 
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bladders. The bladders were delivered to the University of Utah and TEeO researchers for implanta-
tion and evaluation in calves. 
Action 
Within 6 months, the implanted bladders will be retrieved for examination of the neo-intima formed on 
the textured surface. 
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95 before and after sputter etching. 
6.0 INACTIVATED PROJECTS 
ANALYSIS OF THE RETINAL REFLEX 
BATeam Personnel: Dr. H. Clark Beall 
The team1s problem statement received only two suggestions .of appropriate technology items. Neither 
was comprehensive enough to accomplish the thorough analysis of the retinal reflex that was descri 
in the problem statement. The proposed analysis required a large research component in addition to 
the identification of appropriate technology. The development of a successful system, therefore, 
probably not be in the scope of a technology utilization application project. 
ANALYZER OF TISSUE VIABILITY 
BATeam Personnel: Dr. H. Clark Beall 
The RTI team has confirmed the need for a novel, noninvasive probe of tissue viability and has identi-
fied a physiological process that could serve as a unique assay of tissue viability. However, the 
development and testing of the envisioned device appears to require no items of technology unique to 
NASA technology or NASA engineering expertise. 
BIOLOGICAL TISSUE FREEZING SYSTEM 
BATeam Personnel: Dr. H. Clark Beall 
During 1980, several modifications to the freezing system improved the performance of the device 
obtaining strictly linear freezing rates. However I the device cannot automatically eliminate or 
the heat-of-fusion perturbation of the freezing process; therefore, the device offers no outstandi 
competitive advantage over existing commercial freezing units. 
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ESOPHAGEAL PRESSURE TRANSDUCER 
BATeam Personnel: Dr. H. Clark Beall 
Although semiconductor pressure transducers have been identified that are capable of measuring abso-
lute pressure in the range +100 mm Hg to -100 mm Hg, none is small enough to be incorporated within 
an easily swallowed capsule. Because such a capsule would be connected to wires leading outside the 
esophagus, elaborate electrical isolation circuits would be required within the capsule and at the wires' 
external terminals to ensure electrical safety. Both of these considerations would require enlargement 
of the capsule beyond practical limits. 
HEARING AID INTELLIGIBILITY 
BATeam Personnel: Dr. H. Clark Beall 
Improving the intelligibility of hearing aids requires tailored speech processing and noise filtering 
circuitry that have operational characteristics that are unique to virtually each hearing aid wearer. 
These technologies are now based more on microcomputer. software than hardware items. For these 
reasons, one can foresee a research program more than a technology utilization program for the 
eventual development of an appropriate wearable device. 
NEUROMUSCULAR DIAGNOSTIC UNIT 
BATeam Personnel: Dr. James N. Brown, Jr. 
Financial conditions and engineering staff turnover have prevented Miller Medical Electronics, Inc., 
from completing the prototype neuromuscular diagnostic tester for evaluation by the National Institute 
of Neurological and Communicative Disorders and. Stoke of the National I nstitutes of Health (N I H) . 
. The RTI team has discussed the project with JWM, Inc., a medical electronics manufacturer. The team 
has provided JWM with information on the design of the tester, Dr. Somjen's test results, and the 
inter'est by NIH in evaluating the tester as a· diagnostic and therapy monitoring system. JWM ex-
pressed an interest in developing the system, but could not commit resources to the project at this 
time. The RTI team will keep in touch with JWM during 1982. 
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PR ESSURE TRANSDUCER CALI BRATOR 
BATeam Personnel: Dr. James N. Brown, Jr. 
Bell and Howell has decided not to fund an evaluation of the calibrator at Baylor College of Medicine. 
The RTI team, therefore, is inactivating the project as a result of insufficient commercial interest. 
RETRACTOR TOOL FOR BRAIN SURGERY 
BATeam Personnel: Dr. H. Clark Beall 
A concensus opinion could not be reached among the neurosurgeons the team interviewed concerning 
the need for an improved retractor tool and the details of construction and operation. The engineer 
who proposed the initial design of the retractor tool retired from NASA service and cannot be available 
for future prototype construction. and modification. 
SELECTIVE CALL TELEMETRY 
BATeam Personnel: Dr. H. Clark Beall 
NASA engineers pointed out that special integrated circuits and radio frequency circuits were commer-
cially available for the design' of many types of telemetry command devices. This information was for-
warded to the problem originator, together with the names and phone numbers of NASA engineers who 
could advise him concerning his specific needs. 
TEXTURI NG DENTAL IMPLANTS 
BATeam Personnel: Dr. Doris Rouse 
Lack of funding has resulted in reduced activity on this project at Case Western Reserve Dental School 
in the past year. The project is scheduled to be phased out in 1982. 
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WEIGHT ALLEVIATION DEVICE 
BATeam Personnel: Dr. H. Clark Beall 
Rush Presbyterian-St. Lukes Hospital was interested in evaluating the device for elderly stroke vic-
tims, but concluded that design and liability complications outweighed the potential benefits of the 
device. To resolve the liability question, the manufacturer, Melton Corporation, will assume responsi-
bility for evaluation of the device. The RTI team has given Melton the names of rehabilitation centers 
that have expressed an interest in this device. 
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7.0 CONCLUSIONS 
During the reporting period, the RT I Biomedical Applications Team conducted problem-solving and com-
mercialization acitivities for 18 active projects and two commercial transfers. Each of these projects 
has the potential for introducing new or improved commercial medical devices incorporating NASA tech-
nology. The projects selected by the team reflect an emphasis on transferring NASA technology via 
the introduction of commercially available devices. The objective of this commercial emphasis is to 
achieve widespread availability of the devices developed in the technology transfer process. To accom-
plish this commercialization objective most effectively, the RTI team has continued to refine its meth-
odology for technology transfer in medicine. 
I n the past year, the development of a more efficient methodology for the team's activities has been 
an important goal of the RTI team. Implementation of techniques developed by the RTI team for 
reducing the time and costs for transfer of the technology has resulted in a more effective utilization 
of the funds available to the team and NASA field centers as well as to participating agencies and 
manufacturers. Techniques implemented during the reporting period to enhance the team's efficiency 
are described below: 
1. Identify Multiple Applications for Technology 
I n an effort to improve the technology transfer methodology, the team examined critical fac-
tors for NASA technology transfer cases, successful and unsuccessful, from the past several 
years. This study revealed that certain technologies had provided the solution to several 
technical needs in medicine. In many cases ,however, the multiple applications of a tech-
nology had not.been coordinated, resulting in inefficiencies in development and difficulty in 
commercialization. I n those cases where several applications for a technology were identified 
and their development coordinated, the transfer process was more efficient and commerciali-
zation more successful. The RTI team's methodology, therefore, has been modified to include 
an emphasis on the analysis of second applications for technologies identified as solutions 
for team projects. 
Second applications may result in reduced development costs for each project and a more 
attractive business opportunity for potential manufacturers. An example of a successful 
second applications analysis is seen in the hydraulic control technology. A valve developed 
for the Vi king lander experiments met the requirements for high reliability and miniaturiza-
tion necessary for an improved prosthetic urinary sphincter. A second applications analysis 
revealed that this same valve could be used to develop a sphincter for colostomies and a 
control mechanism for a hydraulic penile prosthesis. All three applications of this valve 
technology are now under development by a medical device manufacturer. Currently, the 
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team is evaluating the feasibility of a cerebrospinal fluid control system that utilizes aero-
space technology incorporated in the programmable implantable medication system. 
2. Coordination With Manufacturer/Consumer Committees 
In recent years, several agencies have formed committees to develop performance and safety 
standards for medical devices. These committees include representatives from industry, 
research, and clinical practice. In the past year, the RTI team worked with two of these 
committees to evaluate their potential as sources of new projects with a high probability of 
successful commercialization. The results from both committees were very successful. RTI 
team discussions with the AAMI Committee for Infant Radiant Warmers resulted in a sugges-
tion by NASA engineers for a new temperature probe dislodgement detector. This detector 
is currently being evaluated by manufacturers for incorporation in their radiant heaters. 
As described in Section 3.1, the Aerospace Industries Association established a committee to 
examine the problem of commercial aircraft accessibility for the elderly and disabled. The 
RTI teamls work with this committee resulted in the development and commercialization of an 
onboard wheelchair, a key element in the entire cabin accessibility system. 
The team wi" continue this effective coordination with standards committees by participation 
in the Wheelchair Standards Committee recently formed by the Rehabilitation Engineering 
Society of North America. 
3. Publication in Medical Device Industry Journals 
Access to the medical device industry is an important component in the teamls successful 
conversion of medical problems into commercial solutions based on aerospace technology. 
Many medical deviCe manufacturers, however, remain unaware of NASAls biomedical technol-
ogy transfer program. To inform industry of the NASA program and its potential in the 
development of commercially successful medical devices, the RTI team has made presentations 
and published articles in journals of interest to the medical device industry. 
The response by manufacturers to these presentations and publications has been enthusiastic. 
This efficient and effective technique for accessing the medical device industry will continue 
as an important component of the RTI teamls methodology. 
Results during the past year, therefore, indicate that the teamls use of these three techniques will 
enhance the efficiency of the technology transfer process. The teamls continuing experience in pl'oject 
development andcommercilization wi" result in further refinement of the teamls operating methodology 
in the next year. 
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Perhaps the most important lesson that can be derived from the team's experience in working with 
medical manufacturers is that technology transfer in medicine is extremely complex. The barriers to 
technology transfer are numerous and include the characteristics of medical-device manufacturers, 
Federal regulatory agencies, medical marketing distribution practices, acceptance of a new product by 
the medical community, and all the well-known barriers to technology transfer, in general, and not 
peculiar to the medical field. The team's better understanding of medical manufacturing, marketing, 
and distribution has enhanced its ability to form successful commercialization strategies. However, 
there is still much to be learned concerning this aspect of medical technology transfer and the team 
will continue to expand its interactions with the medical industry in order to gain this understanding. 
Of most importance are ways to effectively handle patents and licensing agreements. More generally, 
all aspects of government/industry interfaces must be understood and facilitated. 
To ensure concentration on medical needs perceived -a~ problems by a significant portion of the medical 
community, the team continues to work with clinicians, researchers, and engineers in 28 medical insti-
tutions, -as well as health agencies such as the National Institutes of Health, the Veterans Administra-
tion, and the Food and -Drug Administration. The expertise and experience of the staffs of these 
institutions and agencies have assisted the team in defining and validating specific medical needs. 
The support and cooperation of the 38 participating medical device manufacturers have resulted in a 
continuity in the transfer projects from problem identification through commercial development. 
Problem-solving activities during the -reporting period have involved eight NASA field centers. This 
extensive interaction between RTI and NASA scientists and engineers has been essential to the iden-
tification of technologies applicable to a variety of medical needs. The RTI team visited five NASA 
field centers during the reporting period. The frequent communication with and visits to the field 
center technology utilization offices have allowed the team to serve as a responsive resource for these 
offices on biomedical. projects. 
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APPENDIX A 
PUBLICATIONS AND PRESENTATIONS 
APPENDIX A 
PUBLICATIONS AND PRESENTATIONS 
Rouse, D. J., Discussion Leader of Workshop Session. Target Group and Human Factor Considerations in 
Product Design. Symposium on· Product Design in the 80 1s. Sponsored by the National Endowment 
for the Humanities, Wilmington, Delaware, March 27, 1981. 
Rouse, D. J. Methodology for NASA Technology Transfer in Medicine. Presented at the 16th Annual 
Meeting for the Association for the Advancement of Medical Instrumentation, Washington, D. C. , 
May 10, 1981. 
Rouse, D. J., J. N. Brown, Jr., and R. P. Whitten. Methodology for NASA Technology Transfer in Medi-
cine. Medical Instrumentation~ Vol. 15, No.4, pp. 234-236. July-August 1981. 
Rouse, D. J. The NASA Technology Transfer Process. I nvited presentation at the National Research Con-
ference on TechnologY and Aging, Racine, Wisconsin, July 29, 1981. 
Rouse,' D. J. Appointed Chairperson of Wheelchair Committee for the Rehabilitation Engineering Society 
for North America, August 1981. 
Brown, J. N. Biomedical Applications - From NASA to Business. Presented at Profit Through Innovations 
Conference, Raleigh, North Carolina, September 10, 1981. 
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APPENDIX B 
TRAVEL 
January 21, 1981 
February 11, 1981 
February 23, 1981 
February 24, 1981 
February 25-26, 1981 
March 5, 1981 
March 17, 1981 
March 23, 1981 
March 25-26, 1981 
March 27, 1981 
, . 
APPENDIX B 
TRAVEL 
Dr. James Brown and Dr. Doris Rouse met with John Samos, ·Sheila Long, and 
Bob Baucom at Langley Research Center to discuss project plans. 
Dr. Clark Beall traveled to the University of Maryland's Emergency Medical Serv-
ices Trauma Center to discuss the need for instrumentation to measure tissue via-
bility in trauma patients. 
Dr. Doris Rouse met with the Stanford University and SRI Applications Teams to 
discuss collaborative projects. 
Dr. Doris Rouse met with Stan Miller, Pat Kirk, Bill Williams, and Daryll 
Rasmussen at Ames Research Center to discuss liquid cooling garment projects. 
Dr. Doris Rouse participated in a Prosthetic Urinary Sphincter project review at 
Parker-Hannifin Corporation, I rvine, California. 
Dr. Clark Beall visited Langley Research Center to discuss RTI team projects 
and to discuss the applicability of photoacoustic spectroscopy for patient monitor-
ing. 
Dr. Clark Beall visited Johns Hopkins Medical Center to document the functioning 
of the tissue-freezing unit. . . 
Dr. Clark Beall participated in a panel discussion at Langley Research Center 
concerning appropriate technology for monitoring temperature gradients within 
human tissue and tumors. 
Dr. Doris Rouse participated in a Programmable Implantable Medication System 
review at the Applied Physics Laboratory in Laurel, Maryland. 
Dr. Doris Rouse led a workshop on "Target Group and Human Factor Considera-
tions in Product Planning" in a Symposium on Product Design in the 19805 in 
Wilminqton, Delaware. 
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April 9-10, 1981 Dr. Clark Beall visited Dr. Kaizer's laboratory at Johns Hopkins University to 
conduct blood-freezing unit experiments. 
April 24, 1981 Mr. Randy Eakes met· with Ray Gilbert, Don Vargo, and Nelson Milder at NASA 
Headquarters to discuss RTI team projects. 
May 8, 1981 Dr. James N. Brown, Jr., met with John Samos at Langley Research Center to 
review the team's activities for the first quarter. 
May 10, 1981 Dr. Doris Rouse presented a paper entitled "Methodology for NASA Technology 
Transfer in Medicine" at the 16th Annual Meeting of the Association for" the 
Advancement of Medical I nstrumentation in Washington, D. C. 
May 15, 1981 Dr. Doris Rouse and Dr. W. H. Clingman met with Don Vargo, Ed Sullivan, and 
Bill Martin, Hercules' technical representative, at NASA Headquarters to discuss 
the use of composite materials in devices for the handicapped. 
June 2-3, 1981 Dr. Clark Beall conducted tissue-freezing experiments and modified the freezing 
unit in Dr. Kaizer's laboratory at Johns Hopkins University. 
June 4, 1981 Dr. Doris Rouse met with Mal Mixon, President of Invacare, and Dr. Colin 
McLaurin at the University of Virginia in Charlottesville to discuss the use of 
composite materials in wheelchairs. 
June 11, 1981 Dr. Doris Rouse met with the Fairchild Burns' New Product Development Group in 
Winston Salem, NC, to discuss commercialization of the aircraft wheelchair. 
July 27-29, 1981 Dr. Doris Rouse led a panel at the Veterans Administration sponsored meeting on 
Wheelchair Research and Manufacturing in Charlottesville, Virginia. 
July 30-August 1, 1981 Dr. Doris Rouse presented a paper on NASA Technology Transfer at the National 
Research Conference on Technology and Aging in Racine, Wisconsin. 
August 20, 1981 Dr. Doris Rouse participated in a planning session for development of a high per-
formance wheelchair at Langley Research Center. 
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September 1-2, 1981 
September 3, 1981 
September 9-10, 1981 
September 10, 1981 
September 15, 1981 
September 18, 1981 
October 2, 1981 
October 6-7, 1981 
October 8, 1981 
December 10-11, 1981 
Dr. Doris Rouse participated in the annual conference of the Rehabilitation Engi-
neering Society of North American (RESNA) in. Washington, D.C. She was 
appointed chairman of the RESNA wheelchair committee. 
Dr. Doris Rouse visited NASA Headquarters to discuss project status. 
Dr. Doris Rouse participated in the Programmable Implantable Medication System 
review at Applied Physics Laboratory in Laurel, Maryland. 
Dr. James N. Brown, Jr., made a presentation entitled "Biomedical Applications--
From NASA to Business, II at the Profit Through Innovations Conference in Raleigh, 
North Carolina. 
Dr. Clark Beall participated in a workshop on I nstrumented Prostheses for I n Vivo 
Measurement of Joint Mechanics sponsored by NIH in Bethesda, Maryland. - --
Dr. Clark Beall and Dr. Doris Rouse participated in the RTI team review at 
Langley Research Center. 
Mr. Charles Eastwood, NASA Headquarters, and Dr. H. Clark Beall met with 
Dr. Allen S. Berson at the Devices and Technology Branch of the National Heart, 
Lung, and Blood I nstitute in Bethesda, Maryland, to discuss potential applications 
of NASA technology in the artificial heart development program. 
Dr. J. N. Brown, Jr., attended the A I AA/NASA-sponsored seminar on Advanced 
Materials Processing and Related Technologies at Langley Research Center. The 
seminar, hosting representatives of the nonaerospace Fortune 500, focused on 
technology transfer. 
Dr. H. Clark Beall met with Dr. F. W. Hegge, Walter Reed I nstitute of Medical 
Research, to discuss the solid-state digital recorder for physiological recording. 
Dr. H. Clark Beall participated in a symposium on corneal topography at Los 
Alamos Scientific Laboratories. The objective of the symposium was to review the 
state-of-the-art and define the requirements for improved methods for character-
izing the corneal topography. 
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APPENDIX C 
PROJECT ACTIVITY SUMMARY 
TABLE C-l. SUMMARY OF BIOMEDICAL APPLICATIONS TEAM ACTIVITIES 
January 1, 1981 - December 31, 1981 
Activity 
New Projects 
I nactivated Projects 
Current Active Projects 
Field Centers Visited 
Field Centers Participating in Team Projects 
Manufacturers Participating 
Medical I nstitutions Participating 
Health Agencies Participating 
I AC I nformation Searches 
Medical Literature Searches 
TABLE C-2. COMMERCIAL TRANSFERS 
Portable Medication I nfusion Pump 
____ =o-~-,-,=,.==_.",,-_._=_ = __ ==== 
C-2 
Number 
5 
11 
18 
5 
8 
38 
28 
23 
5 
13 
Micromed@ 
TABLE C-3. NEW PROBLEMS 
Analyzer of Tissue Viability 
Corneal Topography 
Esophageal Pressure Transducer 
High Performance Wheelchair 
Digital Data Recorder for Physiological Monitoring 
TABLE C-4. 
Analysis of the Retinal Reflex 
Analyzer of Tissue Viability 
Biological Tissue Freezing System 
Hearing Aid Intelligibility 
Esophageal Pressure Transducer 
Neuromuscular Diagnostic Unit 
INACTIVATED PROJECTS 
Pressure Transducer Calibrator 
Retractor Tool for Brain Surgery 
Selective Call Telemetry 
Texturing Dental Implants 
Weight Alleviation Device 
TABLE C-S. ACTIVE PROJECTS AS OF DECEMBER 31, 1981 
-------=-====================================:::::.:==== 
Composite Material Applications 
Corneal Topography 
Detection of a Dislodged Temperature Probe 
Digital Data Recorder 
Fiber Optics System for Knee Surgery 
Flow Sensor for an I nfusion Pump 
High Performance Wheelchair 
Hydrocephalus Shunt--Ventilation 
Implant Materials Testing 
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Low-Cost UV Optical Dosimeter 
Microwave Thermography 
Noninvasive Lung Diagnosis 
Ophthalmic Screening Device 
Portable Cooling System for Quadriplegics 
Programmable Implantable Medication System 
Prosthetic Urinary Sphincter 
Texturing for Percutaneous Connectors 
Texturing Surfaces for Cardiovascular Prostheses 
APPENDIX D 
PROBLEM STATEMENTS 
APPENDIX D 
PROBLEM STATEMENTS 
ANALYZER OF TISSUE VIABILITY 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
There are many situations of clinical care in which a physician wishes to determine the present state 
of viability of a tissue or an organ. An instrument is needed that can quantify the state of recovery 
of human tissue following trauma, burns, or surgery. 
solution 
A device is required that objectively measures a pertinent factor of basic metabolism. The oxidution 
state of the cytochromes of the mitochondria is an example of a parameter that can be measured instru-
mentally and that is a sensitive indicator of basic metabolism. 
NASA Technology 
Photoacoustic spectroscopy is a newly developing technology that can be utilized to sample the oxida-
tion/reduction ratio of cytochromes in living tissue. 
Principles 
Dr. Barry Burns, University of Maryland Trauma Center, Baltimore, Maryland. 
Dr. John Cantrell, NASA Langley Research Center, Hampton, Virginia. 
Cost to NASA 
No cost is anticipated within the- next 3 months. 
Commercialization Strategy 
No strategy has yet been formulated. 
Status 
Evidence from theory, numerical calculations, and the scientific literature show that the proposed new 
instrumentation is feasible. 
Action 
A demonstration of the operation of the optical transducer is being scheduled at Langley Research 
Center. 
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CORNEAL TOPOGRAPHY 
BATeam Personnel: Dr. H. Clark Beall ' 
Problem 
The cornea of the eye is the tough, transparent layer through which light rilys must first pass upon 
entering the eye. Trauma and diseases can distort the spherical surface of the cornea to such iln 
extent that corneal transplant surgery is required to correct the accumulated refractive error. A new 
surgical procedure, radial keratotomy, is an alternative to corneal transplant surgery. Both proce-
dures require that the surgeon be able to precisely gauge the topography of the corneal surface 
before, during, and after the surgery. 
Solution 
Several optical devices are now available that reflect light from the front surface of the cornea; A 
photographic record can be made of the reflected light pattern; the photo can later be anCllyzed on an 
optical bench to quantify, in diopter units, the refractive power of a dozen points on the cornea. An 
instrument is desired that can gauge in real time the actual contour, or topography, of the cornoal 
surface. 
NASA Technology 
Laser illumination of objects offers several unique characteristics that could be applied to the gauging 
of corneal topography. 
Principals 
Dr. J. Rowsey, surgeon, McGee Eye Institute, Oklahoma City, Oklahoma. 
Mr. J. D. Doss, Los Alamos National Laboratory, New Mexico. 
Mr. Bert Kortegaard, Los Alamos National Laboratory, New Mexico. 
Cost to NASA 
Discretionary funds are available at Los Alamos National Laboratory for prototype and development worl< 
on a new device for noncontact contouring of the cornea of the eye. The University of Oklahoma has 
been funded by the National Eye Institute to evaluate corneal topography measurement techniques. No 
a,dditional funds will be required from NASA. 
Commercialization Strategy 
There appears to be a ready market for a new generation of gauging devices that could be used 
during surgery. Contacts have already been made with several manufacturers who could produce such 
devices. 
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Slatus 
Dr. Rowsey called a workshop on this subject at Los Alamos National Laboratory on December 11, 1981. 
Manufacturers and academicians described the operation of devices that have been designed to gauge 
corneal contour. Although slow, most of the devices can measure corneal contour if the contour is 
regular, i. e. for fitting contact lens. However, for corneal surfaces that have been irregularly dis-
torted by trauma or disease, the presently used reflective devices are of no use. 
Action 
The RTI team will identify NASA technology that can be utilized in the design of a new generation of 
devices for gauging corneal topography. The team will work with personnel at Los Alamos National 
Laboratory and the University of Oklahoma in the implementation of the technology into a working 
prototype. . 
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CORNEAL TOPOGRAPHY 
• INSTRUMENT EASILY GAUGES CORNEAL 
CURVATURE FOR CONTACT lENS 
• NEW INSTRUMENT NEEDED FOR REAl-TIME 
GAUGING OF CORNEA TOPOGRAPHY 
• APPROPRIATE NASA TECHNOLOGY: 
OPTICAL GAUGING 
DIGITAL IMAGE PROCESSING 
TV DISPLAY 
• McGEE EYE INSTITUTE, OKLAHOMA CITY 
. lOS ALAMOS SCIENTIFIC LABORATORY 
Comeascope 
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RNEAl TOPOGRAPHY 
~ DISTORTED PLACIDO REFLECTIONS FROM 
CORNEASCOPE DIfFICULT TO ANALYZE 
NEW SYSTEM NEEDED FOR .REAL-TIME 
GAUGING OF CORNEAL TOPOGRAPHY 
APPROPRIATE NASA TECHNOLOGY: 
OPTICAL GAUGING 
DIGITAL IMAGE PROCESSING 
TV DISPLAY 
McGEE EYE INSTITUTE, OKLAHOMA CITY 
LOS ALAMOS SCIENTIfIC LABORATORY 
B 
A. 
c 
(omeascope photographs of three stages of I<eratoconus: 
A. early B. progressive C. severe. 
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DIGITAL DATA RECORDER FOR PHYSIOLOGICAL MONITORING 
BATeam Personnel: Dr. H. Clark Beall 
Problem 
There are approximately 20. million insomnia sufferers in the United States. 
40 percent of people over 60 years of age have IIsleep apena,lI an inadequate 
to a temporary irregularity of respiration. The apena episodes cause recurrent 
sleep at night. The resultant lack of restful sleep causes confusion, drowsiness, 
of attention during daylight hours. This is especially a problem in the elderly. 
to study the psychology and physiology of sleep have traditionally brought 
where sophisticated instrumentation can record the physiological changes that occur 
sleep stages. They have found, however, that the laboratory environment affects 
of most patients. What is required is a means of recording physiological data in 
in order to reduce costs and improve the quality of data. 
Principals 
Dr. Elliot D. Weitzman, Montefiore Hospital and Medical Center, Bronx, New York. 
Dr. Fred Hegge, Walter Reed Army Medical R&D Command I Washington I DC. 
Solution 
Most sleep researchers record data on multipen stripchart recorders. These 
expensive and not at all portable. Improved sleep monitoring requires a new system 
operated, solid-state, small digital data recorders that can be distributed to patients for use 
The recorders can be returned to the laboratory for readout of the data. 
NASA TechnOlog
n 
. 
NASA TM:8 267 1 describes a digital, solid-state recorder that features a selfcontained 
circuitry, a 2048-word digital memory, an 8-bit analog-to"digital converter, and an operating 
of several weeks. Although the device is used in the NASA Space Shuttle as a temperature 
the temperature transducer could be replaced with other transducers that are appropriate 
ing parameters such as respiration rate, activity I muscle activity, eye movement, or body 
Cost to NASA 
No cost to NASA is anticipated for the biomedical application of this device. 
Commercialization Strategy 
Descriptive literature has been mailed to several prospective manufacturers. 
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Status 
The RTI team has discussed this system with Dr. Weitzman (for sleep research) and with Dr. Hegge 
(for physiological monitoring in the field). Both researchers plan to utilize the recorder in their 
research. 
Action 
The base®station readout facility for the digital recorder has been recently redesigned to operate with 
an Apple microcomputer. The engineers at the NASA Ames Research Center will provide the new 
hardware diagrams and software listing for the base station as soon as the system has been debugged. 
The RTI team will continue discussions with manufacturers and researchers. 
Reference 
·1. Westbrook, R. M., L. D. Bennett, R. A. Steinhauer, and G. J. Deboo. A Solid-State Digital 
Temperature Recorder for Space Use. NASA TM-81267, NASA Ames Research Center, 1981. 
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DIGITAL DATA RECORDER FOR 
PHYSIOLOGICAL MONITORING 
• RECORDING OF PHYSIOLOGICAL PARAMETERS 
DURING SLEEP 
• TEMPERATURE DATA RECORDER DEVELOPED BY . 
NASA AMES RESEARCH CENTER FOR SHUTTLE 
FLIGHTS 
• LIGHT-WEIGHT, SMAll RECORDER WITH NO 
. ATTENDANCE REQUIREMENT . 
• WALTER REED INSTITUTE OF MEDICAL 
RESEARCH 
ALBERT EINSTEIN COllEGE OF MEDICINE 
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I ITAL DATA RECORDER FOR 
P YSIOLOGICAL MONITORING 
• RECORDING OF PHYSIOLOGICAL PARAMETERS 
DURING SLEEP 
• TEMPERATURE DATA RECORDER DEVELOPED BY 
NASA AMES RESEARCH CENTER FOR SHUTTLE 
FUGHTS 
• UGHT-WEIGHT, SMALL RECORDER WITH NO 
ATTENDANCE REQUIREMENT 
• WALTER REED INSTITUTE OF MEDICAL 
RESEARCH 
ALBERT EINSTEIN COLLEGE OF MEDICINE 50 
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Flight Recorder # 1 
Start, Room Temperature 
Moscow 
Spacecraft 
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Temperature 
Transporter 
Data Readout, 
Moffett Field, CA 
Return of Recorder 
via Airlines, 
Moscow-Tokyo-San Francisco 
10~~~~~~----~----~----~--~ 
o 1 2 3 4 5 6 
Time, weeks 
Data from US-USSR Cosmos satellite flights 
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ESOPHAGEAL PRESSURE TRANSDUCER 
BATeam Personnel: Mr. R. E. Eakes 
Problem 
The insertion of a nasogastric balloon catheter to measure esophageal pressure is extremely uncomfort-
able for the majority of patients undergoing pulmonary function testing and simply cannot be accom-
plished in others due to activation of the IIgag li reflex. I n addition, the balloon often ruptures 
during insertion arId the patient is subjected to the ·same ordeal once again. 
Solution 
An alternate method of obtaining esophageal pressure measurements during pulmonary function testing 
is needed . 
. NASA Technology 
A problem statement was distributed to a" NASA field centers in January 1981. 
Principals 
Dr. Nelson Leatherman, Pulmonary Function Laboratory, Duke. University Medical Center, Durham, 
North Carolina. . 
Dr. John L. Patterson, Jr., Professor of Medicine; Division of Cardiopulmonary Laboratories and 
Research I Medical College of Virginia, Richmond, Virginia. 
Cost to NASA 
No cost is anticipated .. 
Commercialization Strategy 
A significant improvement in esophageal pressure measurement for pulmonary function testing would 
have possible applications in esophageal motility and esophageal sphincter studies as we". There are 
several manufacturers of equipment for the latter two categories who are possible sources of commer-
cialization .. 
Status 
---A problem statement was circulated to a" NASA field centers in January 1981. 
Action 
Problem statement responses wi" be reviewed with the principals as they are received. 
HIGH PERFORMANCE WHEELCHAIR 
BA Team Personnel: Dr. Doris Rouse 
Problem 
Approximately 700,000 people in the United States currently rely on wheelchairs for mobility. The 
limitations of available chairs include heavy weight, frequent breakdowns, and limited lifetime, resulting 
in high life-cycle costs. Recognizing these problems,· the Veterans Administration and the National 
I nslitute on HandiCapped Research have funded several wheelchair research projects. Most of these 
projects are component oriented .. Few projects involve a full-scale deveopment effort, from analysis of 
requirements through prototype fabrication. and. evaluation. 
Solution 
The use of improved materials as. well as computer analysis and simulation could result in an advanced, 
lightweight wheelchair.· 
NASA Technology ... 
Structure analysis ·computer programs used In ·the design of aerospace vehicles would be useful in the 
design of an advanced wheelchair. ··Graphit.e composite materials developed for aerospace could be 
incorporated in an ·advanced. chair to reduce weight. 
Principals . . . ..... . 
Mr. Robert Baucom, MaterialsApplications Br.anch, NASA Langley Research Center, Hampton, Virginia. 
Dr. Colin McLaurin,. University: of Virginia-:-:Rehabilitation Eng·ineering Center, Charlottesville, Virginia. 
Cost to NASA .... 
In ·1981, NASAa·llqcateq .$6{),000 to this·~ project.· . A.nadditional $40,000 will be expended by the 
University of Virginia Rehabilitation Engineering Center Jor· the design and evaluation of the chair in 
lhe first yea.r. Funding ·for ~he University of Virginia's participation is provided by the National 
Institute of HandiC~pped Rese~rch.·· . 
Commercialization Strategy . 
Dr. Doris Rouse met . with Mal· Mixon, President Of Invacare Cqrporation, and Dr. McLaurin to discuss 
commercializa.tion of the chair. Invacare IS very. interested in rnarketing the chair, if the price is 
r'easonable. Invacare invited participaritsin this project· to visit their plant in Ohio to discuss possible 
prototype fabrication. The RTI team ha;; .also discussed participation in this project with other wheel-
chair manufacturers .. 
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Status 
An initial planning meeting was held at Langley· Research Center on August 20, 1981. The design 
criteria and performance goals have been documented by the University of Virginia. Dr. Aileen Rogers 
of Drexel University submitted a proposal to Langley to perform the computer analysis in the project. 
Dr. Rogers plans to do this work at Langley Research Center. 
Action 
A review and planning meeting for the project is scheduled for January 1982. The RTI team will 
participate in this meeting. Preliminary deslgn~ are scheduled to be completed by August 1982. 
Otto Fedor at Kennedy Space Center has contacted the RTI team about the development of an ad-
vanced wheelchair. RTI will keep him informed of the Langley project and will facilitate his group's 
participation. 
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